Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation. by DI RAIMONDO, D. et al.
 Current Pharmaceutical Design, 2012, 18, 4385-4413 4385 
 1873-4286/12 $58.00+.00  © 2012 Bentham Science Publishers 
Effects of ACE-Inhibitors and Angiotensin Receptor Blockers on Inflammation 
D. Di Raimondo*, A. Tuttolomondo*, C. Buttà, S. Miceli, G. Licata* and A. Pinto 
U.O.C. di Medicina Vascolare - * U.O.C. di Medicina Interna e Cardioangiologia, Dipartimento Biomedico di Medicina Interna e 
Specialistica, Università degli Studi di Palermo 
Abstract: The role of inflammation in cardiovascular disease and in hypertensive disease above all, is complex. Several studies confirm 
that activation of renin-angiotensin-aldosteron system (RAAS), through increase in the production of angiotensin II (Ang II), is closely 
related to local vascular inflammation. Over the BP lowering effects of anti-hypertensive treatments, several ancillary effects for every 
class may be found, distinguishing the various drugs from one another. Given the pro-inflammatory effects of Ang II and aldosterone, 
agents that interfere with the components of RAAS, such as ACE inhibitors, Angiotensin Recpetor Blockers (ARBs), and mineralocorti-
coid receptor antagonists (spironolactone or the more selective eplerenone), represent logical therapeutic tools to reduce vascular inflam-
mation and cardiovascular risk, as suggested in large clinical trials in patients with hypertension and diabetes. Regarding ACE inhibitors, 
actually there is no convincing evidence indicating that ACEi’s reduce plasma levels of major inflammatory markers in hypertension 
models. Lack of evidence concerns especially these inflammation markers, such as fibrinogen of CRP, which are less closely related to 
atherosclerotic disease and vascular damage and conversely are affected by several more aspecific factors. Results obtained by trials ac-
complished using ARBs seem to be more univocal to confirm, although to great extent, these is an anti-inflmmatory effect of drugs bock-
ing AT1 receptor. In order to strictly study the effects of blockage of RAAS on inflammation, future studies may explore different strate-
gies by, for example, simultaneously acting on the ACE and the AT1 angiotensin receptors. 
Keywords: Renin-angiotensin-aldosteron system (RAAS), ACE inhibitors, angiotensin recpetor blockers, inflammation. 
INTRODUCTION  
 Atherosclerosis and inflammation are extremely linked to one 
another [1]. In the last decades, increasing evidence has been accu-
mulated about the relationship between inflammation and the de-
velopment of essential hypertension.  
 Chronic Systemic Low-level Inflammation, defined as modest 
(2-4-fold) elevations in circulating levels of pro-inflammatory and 
anti-inflammatory cytokines, naturally occurring cytokine antago-
nists, and acute-phase proteins, as well as minor increases in the 
counts of neutrophils and natural killer cells [2], represents an 
emerging condition, that accompanies aging such as several patho-
logic conditions and atherosclerosis itself [3].  
 The pathogenesis of essential hypertension has been extensively 
studied; we know that hypertension is a multi-factorial disease re-
sulting from the effect of the combination of both environmental 
and genetic factors. It has been demonstrated that several factors 
may contribute to the development of hypertension including ex-
cess dietary salt and/or alcohol intake, cigarette smoking, stress, 
aging, genetics factors and family history, obesity/insulin resis-
tance, physical inactivity, as well as high saturated fat diet.  
 In the recent years, the suggestion that hypertension-associated 
vascular disease could be partly due to an inflammatory process, 
and that the chronic systemic low-grade inflammation may play a 
role in the pathophysiology of elevated blood pressure found even 
more supporting data [4].  
 Taking into account that essential hypertension is a relevant 
challenge for the public health because of its high prevalence, 
which is estimated to increase to 29% by the year 2025 [5], deeper 
knowledge of the cause leading to vascular damage and clinical 
appearance may conduce to significant improvement of the preven-
tion of organ damage and vascular event related to hypertension, 
leading to death and disability throughout the world [5]. 
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 The analysis of the role of inflammation in the pathogenesis of 
cardiovascular damage and especially in hypertensive disease, is 
really complex. The inflammatory process, infact, consists of a 
complex set of interactions between inflammatory cells, which 
leads to increased expression of adhesion molecules, cytokines, 
chemokines, matrix metalloproteinases and growth factors. All 
these elements variously interact with the vascular wall compo-
nents, and mainly with endothelial cells, that are widespread recog-
nized as an intricate laboratory in which vascular motion, local 
platelet aggregation, coagulation, and inflammation are determined.  
 Among the well-known pathophysiological elements leading to 
essential hypertension, renin-angiotensin-aldosteron system 
(RAAS) certainly has a main role. Latest studies confirm that acti-
vation of RAAS, through increase in the production of angiotensin 
II (Ang II), is closely related to local vascular inflammation [6]. 
Furthermore, aldosterone (ALD) and/or mineralocorticoid receptor 
(MR) activation cause oxidative stress and vascular inflammation 
[7]. Embracing these theories appear clear how RAAS is a pro-
inflammatory system. Obviously, not all the supposed pathophysi-
ological burden due to inflammation in leading essential hyperten-
sion could be ascribed to RAAS; several molecular mechanisms, 
such as oxidative stress with production of reactive oxygen species 
(ROS), and activation of inflammatory transcription factors, e. g. 
the nuclear transcription factor Nuclear Factor B (NFB) also play 
a crucial role [2]. 
 If it is true that RAAS is a pro-inflammatory system, then the 
drugs that antagonize RAAS may be retained as anti-inflammatory 
drugs, as consequent of reducing vascular inflammation.  
 We know that in the treatment of patients with hypertension, as 
stated by the latest guidelines [8], all the available classes of anti-
hypertensive drugs may be used, with the main objective to reduce 
possible blood pressure (BP) levels as soon as trying to lower at the 
same time added cardiovascular risk. But over the BP lowering 
effects of anti-hypertensive treatments, several ancillary effects for 
every class may be found, distinguishing the various drugs from 
one another. 
 Given this, establishing the anti-inflammatory effects of ACE-
inhibitors (ACE-i) and Angiotensin Recpetor Blockers (ARBs) may 
be essential for future therapeutical choice. Furthermore, among 
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medications of the same therapeutic class, generally having a simi-
lar mechanism of action, may be some differences. So, not neces-
sarily, all the ACE-i and all the ARBs may be identified with simi-
lar ancillary and anti-inflammatory properties. 
 Aim of the present review is, first of all, to overview the state of 
the art of inflammatory mechanisms proposed to explain the patho-
genesis of essential hypertension; second, to analyze the character-
istics of the main ACE-i and ARBs and finally to discuss the effects 
of ACE-i and ARBs on inflammation, the differences among the 
various drugs of the two classes and the hypothetical implications 
for future therapeutic approaches. 
PART I - IS ESSENTIAL HYPERTENSION AN INFLAM-
MATORY DISEASE? 
 Several hypotheses have been proposed to explain the main 
pathogenic mechanisms of essential hypertension [9]. 
 Essential hypertension is commonly believed to be initiated by 
neural or humoral stimuli, which lead to positive feedback mecha-
nisms, such as changes in pressure-natriuresis in the kidney, initia-
tion of the autoregulatory response, and vasoconstriction, because 
of vascular hypertrophy. [7,10].  
 Recently, Johnson et al [9], focusing on the renal mechanisms 
that underlie the defect in pressure natriuresis in essential hyperten-
sion and assuming that the pathogenesis of most forms of hyperten-
sion (including primary and secondary) involves an important role 
of the kidney, proposed a pathway which unites many of the previ-
ous hypotheses on the pathophysiology of essential hypertension 
and consists of 3 phases. A first pathway: glomerular filtration rate-
dependent (renoprival mechanism), a second pathway: transport 
mechanisms (stimulation of sodium reabsorption in the collecting 
duct) and a third pathway: renal ischemia (vasoconstriction, oxida-
tive stress and inflammation). The three pathways and the following 
theories are widely discussed in [9], summarizing the first phase is 
initiated by episodes of renal vasoconstriction, induced in most 
cases by hyperactivation of the sympathetic nervous system and 
activation of the RAS. Whereas, during the second and the third 
phases, tubulointerstitial inflammation, which is associated with 
interstitial T cell and macrophage recruitment, local Ang II forma-
tion and generation of ROS, contributes to preglomerular vascular 
disease and intrarenal vasoconstriction. These processes contribute 
to a change in local vasoconstrictor-vasodilator balance favoring 
sodium retention [11,12].  
 Even though the aetiology of hypertension has been investi-
gated in depth, the pathophysiology is multifactorial and far from 
being clear. Immunopathogenic mechanisms, in particular T cells, 
have been demonstrated to play an important role in the genesis of 
hypertension. Experimental models with Ang II-infused mice lack-
ing T- and B cells showed that they had blunted hypertension and 
did not develop vascular dysfunction [13] T cells function seems to 
be regulated by an endogenous RAS, which affects nicotinamide 
adenine dinucleotide phosphate oxidase (NADPH) activity and 
production of inflammatory cytokines, such as tumor necrosis fac-
tor-alpha (TNF-). [14] Additionally, recent reports show increased 
monocyte adhesion to endothelial cells from spontaneously hyper-
tensive rats and elevated levels of activated circulating monocytes 
in hypertensive patients. [15,16]. 
 Interest has also been directed toward oxidative stress and re-
duced bioavailability of nitric oxide (NO), as a result of systemic 
and localized inflammatory responses, which lead to vasoconstric-
tion and impaired vascular function. The overall association of 
inflammation and blood pressure has been indicated in many cross-
sectional studies with never-treated essential hypertensives, who 
exhibited greater plasma levels of C-reactive protein (CRP). [16,17] 
However, research during the last decade has shed light on the as-
pect of the possible causal relationship between CRP and essential 
hypertension, because of its close relationship with markers of arte-
rial stiffness. [18]. 
 At least four novel mechanisms seem to be closely related to 
vascular inflammation in hypertension: 1) ROS production and 
redox-sensitive inflammatory response; 2) NFB activation; 3) Pro-
inflammatory activities of endothelin-1 (ET-1); 4) Pro-inflam-
matory activities of RAAS. 
 In the following part of this review we will be briefly analyze 
the first three; the action of Ang II, aldosterone and of the other 
components of RAAS on inflammation and on vascular damage 
will be deeply analyzed later. 
1) Reactive Oxygen Species (ROS) Production, Redox-sensitive 
Inflammatory Response and Vascular Inflammation 
 Increased production of reactive oxygen species (ROS), such as 
superoxide anion (•O2-), hydrogen peroxide (H2O2), hydroxyl 
radical (OH•), NO, and peroxynitrite (ONOO-) leading to cellular 
oxidative stress is linked to numerous pathologies including cancer, 
diabetes, and neurological diseases [19,20]. 
 The common term “oxidative stress”, that was first defined as 
“a disturbance in the pro-oxidant-antioxidant balance in favour of 
the former” [21]. Although this definition has been widely accepted 
for over 25 years, this description of oxidative stress is under scru-
tiny and modifications to this meaning have been proposed by sev-
eral authors. For example, because of the complexity of cellular 
redox balance, it has been argued that the term “oxidative stress” 
defines a simple pro-oxidant versus antioxidant definition and that 
the description of an “oxidant stress” is helpful only if the molecu-
lar details of the redox imbalance are known. For these reasons, 
definitions of oxidative stress and oxidative imbalance are actually 
ongoing and commonly describe conditions involving increased 
ROS levels. 
 Referring to vascular pathophysiology, (see Fig. 1) in the vas-
cular wall a major source of vascular ROS is NADPH, which is 
produced in endothelial cells, vascular smooth muscle cells 
(VSMCs), fibroblasts, adventitial cells, and monocytes/macro-
phages. Several researches on experimental models of hypertension 
in which antioxidant treatment reduced blood pressure and Ang II-
induced end-organ damage, have shown an established relationship 
between oxidative stress and blood pressure [22]. Nevertheless, the 
distinct properties between •O2- and H2O2 and their different sites 
of distribution mean that different species of ROS can activate dif-
ferent signaling pathways, which lead to divergent, and potentially 
opposing, functional responses. For example, increased .O2- levels 
inactivate the vasodilator NO leading to endothelial dysfunction 
and vasoconstriction, characteristic of many vascular diseases, in-
cluding hypertension. It is widely accepted that production of NO 
by the endothelium maintains the vasculature in a state of vasodila-
tion, whereas lack of the endothelial NO synthase gene entails mild 
hypertension [23].  
 Furthermore, Ang II has been reported to increase O2 produc-
tion in endothelial cells, VSMCs and adventitial fibroblasts through 
activation of NADH/NADPH oxidase. Such production impairs the 
balance between relaxing and contracting factors released from the 
endothelium and results in increased tone of the smooth muscle 
[24].  
 In addition to the activation of NADPH oxidase by various 
stimuli, polymorphisms in this enzyme’s subunits are associated 
with increased atherosclerosis and hypertension. In particular, re-
cent studies have demonstrated that hypertensive patients carrying 
the -930(A/G) polymorphism are more susceptible to oxidative 
stress [25].  
 The C242T CYBA polymorphism, and in the Japanese popula-
tion, the G(-930)A polymorphism of CYBA, may be novel genetic 
markers associated with the pathogenesis of hypertension [26].  
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 ROS potentially influence every stage of inflammation includ-
ing vascular permeability, leukocyte recruitment, cell growth and 
fibrosis, modulating vascular tone, and remodelling [27,28]. 
Physiologically, NAD(P)H oxidase-derived ROS have been impli-
cated in the regulation of vascular tone by modulating vasodilation 
directly (H2O2 may have vasodilator actions) or indirectly by de-
creasing NO bioavailability through quenching by .O2- to form 
ONOO- Because of decreased NO bioavailability, increased O2 
production in the endothelium results in the stimulation of inflam-
matory process, endothelial dysfunction, and altered vasodilation 
[27,28,29]. These processes are mediated via multiple intracellular 
proteins, enzymes, and transcription factors, such as NF-B, activa-
tor protein-1 (AP-1) and hypoxia-inducible factor 1 (HIF-1), which 
can be activated by ROS.  
 ROS, through the regulation of HIF-1, are also important in O2 
sensing [30], which is essential for maintaining normal O2 homeo-
stasis. In pathological conditions, ROS are involved in inflamma-
tion, endothelial dysfunction, cell proliferation, migration and acti-
vation, extracellular matrix deposition, fibrosis, angiogenesis, and 
cardiovascular remodeling, important processes contributing to 
cardiovascular and renal remodeling in hypertension, atherosclero-
sis, diabetes, cardiac failure, and myocardial ischemia/reperfusion 
injury [31]. 
 The relationship between oxidative stress and increased blood 
pressure has been demonstrated in many models of experimental 
hypertension. Animal models show an increased ROS formation 
preceding development of hypertension. The produced ROS con-
tribute to the activation of signalling molecules, such as mitogen-
activated protein kinase, protein tyrosine phosphatases, protein 
tyrosine kinases, and transcription factors, whereas levels of anti-
oxidant enzymes are reduced in experimental hypertension. These 
cascades participate in VSMC growth and migration, expression of 
pro-inflammatory mediators, and modification of extracellular ma-
trix [32]. 
 Ang II is a major mediator of oxidative stress and consequently, 
of reduced NO (nitric oxide) bioavailability. More specifically, Ang 
II signalling, via Ang II type 1 (AT1) receptors, is upregulated in 
VSMC of hypertensive patients, leading to the activation of vascu-
lar NADPH oxidase. In VSMC, furthermore, Ang II regulates the 
expression of redox-sensitive inflammatory genes, such as those 
encoding monocyte chemoattractant protein-1 (MCP-1) and inter-
leukin-6 (IL-6), inducing an hypertensive response in several ex-
perimental models [33]. 
2) Nuclear Factor B (NFB) Activation and Vascular Inflam-
mation 
 The transcriptional response in innate and adaptive immunity is 
dependent on the activation of various transcription factors. 
 A crucial transcription factor is NF-B, which controls the tran-
scription of many genes with an established role in atherosclerosis, 
such as cytokines, chemokines, adhesion molecules, acute phase 
proteins, regulators of apoptosis, and cell proliferation. NF-B was 
discovered in 1986 in the laboratory of David Baltimore [34] and 
has from that time been the subject of extensive research. NF-B is 
the general name for a family of transcription factors consisting of 5 
members: p65 (RelA), c-Rel, RelB, NF-B1 (p50 and its precursor 
p105), and NF-B 2 (p52 and its precursor p100), all the members 
of the family share a significant structural homology. 
 NF-B is involved in all the phases of the atherosclerotic proc-
ess, from initiation to foam cell formation, cell death and formation 
of the necrotic core, and finally proliferation of smooth muscle cells 
and fibrous cap formation [35]. NF-B may not only contribute to 
the different stages in atherosclerosis development it is also likely 
that its contribution will be cell type- dependent, leading to differ-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Reactive oxygen species (ROS) production and vascular inflammation. 
4388    Current Pharmaceutical Design, 2012, Vol. 18, No. 28 Di Raimondo et al. 
ential regulation of different genes (e.g. in endothelial cells versus 
macrophages) [35]. 
 NF-B is particularly important in vascular inflammation, as it 
regulates the transcription levels of several proinflammatory genes.  
 Ruiz-Ortega et al [36] demonstrated that Ang II activates NF-
B via AT1 and AT2 in VSMCs, although NF-B-mediated tran-
scription occurs mainly through AT1 [36]. In turn, NF-B stimu-
lates angiotensinogen and Ang II gene expression, thereby partici-
pating in the inflammatory responses related with Ang II. The im-
portance of NF-B in inflammation has been suggested by experi-
mental models of atherosclerosis and hypertension, demonstrating 
that NF-B inhibition reduces Ang II-induced expression of IL-6, 
vascular cell adhesion molecule-1 (VCAM-1) and ameliorated vas-
cular injury [37].  
 In VSMC from AT1a receptor knockout mice, Ang IV, an an-
giotensin related peptide, also activated NF-B pathway via AT4 
receptors and increased the expression of proinflammatory factors 
under NF-B control, such as MCP-1, IL-6, TNF-, intercellular 
adhesion molecule-1 (ICAM-1), and tissue plasminogen activator 
inhibitor-1 (PAI-1) [38]. Moreover, NF-B also plays a key role in 
other phases of inflammation cascade, such as Ang II-induced mi-
gration and proliferation of VSMCs, both of them under normal 
physiological conditions and following vascular injury [39]. Never-
theless, NF-B drives factors that may protect against atherosclero-
sis, such as IL-6 and IL-10, but also factors that enhance atheroscle-
rosis, such as IL-1, IL-12, and IFN [35]. These findings may lead 
to a more complete portrayal of NF-B in inflammation showing a 
role in the onset as well as the resolution of inflammation. The im-
plications for vascular inflammation in atherosclerosis remain to be 
elucidated. 
3) Pro-inflammatory Activities of Endothelin-1 (ET-1) 
 Since the first identification in 1985 by Hickey et al [40] of a 
vasoconstrictor peptide secreted by endothelial cells, today the en-
dothelin system includes several peptides produced by many or-
gans. ET-1 is the most abundant and important ET produced by 
vascular cells. It is secreted abluminally by endothelial cells toward 
underlying smooth muscle, and acts in a paracrine or autocrine 
manner.  
 ET-1 acts by stimulating ETA and ETB receptors. Both ETA 
and ETB receptors are localized on vascular smooth muscle cells 
where they induce their vasoconstrictor, proliferative and hypertro-
phic action. ETA receptors are the predominant ET vasoconstrictor 
receptors in arteries. 
 Vasoconstrictor ETB receptors are present in the veins and 
pulmonary vessels [41] in larger numbers than in arteries, although 
ETA still predominate over ETB receptors in these vessels. ETB 
receptors are also localized on endothelial cells and act through the 
production of NO and prostacyclin to exert a vasodilator effect. 
 The endothelin system has been demonstrated to have a patho-
physiological role in several conditions, including hypertension, 
atherosclerosis, coronary artery disease, heart failure, subarachnoid 
hemorrhage, diabetes, primary pulmonary hypertension, pulmonary 
fibrosis, scleroderma, renal failure, prostate cancer and its metasta-
sis, etc. [42]  
 Regarding the aim of this review, it should be noted that ET-1 
not only induces vasoconstriction (being implicated in pathogenesis 
of essential hypertension), but that it is also a potent growth-
promoting agent, and, finally, should be underlined how several 
studies indicate ET-1 as an important mediator of chronic vascular 
inflammation. 
 Experimental data provide evidence that ET-1 induces vascular 
inflammation by multiple pathways in young animals, such as an 
increase in blood vessel wall expression of VCAM-1 and MCP-1, 
macrophage infiltration and increase in the activation of transcrip-
tion factors AP-1 and NF-B [43]. 
 Ang II-induced inflammation mediated by NF-B might in-
volve ET-1 because when NF-B was inhibited, there was a parallel 
suppression of ET-1. Also ROS are potent stimulators of ET-1 syn-
thesis by endothelial cells and VSMCs [42,43]. ET-1 activates 
NADPH oxidase, as well as other sources of ROS, including xan-
thine oxidase and mitochondria, to produce increased oxidant stress 
in VSMCs and blood vessels. ET-1-induced oxidative stress elicits 
inflammatory responses and contributes to the vascular remodelling 
and endothelial dysfunction found in hypertensive models that ex-
hibit an ET-mediated component. Moreover, Verma et al [44] indi-
cated an interesting relationship between ET-1, CRP, and IL-6, 
suggesting that the proatherosclerotic and inflammatory effect of 
CRP could be mediated by the action of ET-1 and IL-1. Interest-
ingly, Hocher et al [45] reported that ET-1 induces chronic inflam-
mation with increased tissue macrophages and lymphocytes infiltra-
tion, as well as expression of inducible NO synthase, the effect of 
which appears to counteract the vascular effects of ET-1. These 
data increase our knowledge of the connections between ET-1 
pathway and NO metabolism and may have great impact on future 
therapeutic strategies. ETA receptor antagonism decreases oxida-
tive stress, normalizes hypertrophic remodelling, decreases collagen 
and fibronectin deposition, and reduces ICAM-1 levels in the vas-
culature of aldosterone-infused rats [44]. 
PART II - ROLE OF THE RENIN-ANGIOTENSIN-
ALDOSTERONE SYSTEM ON SYSTEMIC AND VASCU-
LAR INFLAMMATION  
 RAAS plays a main role in the preservation of hemodynamic 
stability through the regulation of extracellular fluid volume, so-
dium balance and cardiac and vascular trophic effects. In addition, 
overactivity of the RAAS is associated with the development of 
atherosclerosis, hypertension, left ventricular hypertrophy, and 
cardiovascular events, such as myocardial infarction, stroke, con-
gestive heart failure, and nephrosclerosis. 
 Angiotensin II (Ang II), the major effector peptide in the 
RAAS, is recognized for its facilitative role in the mechanisms 
underlying cardiovascular and renal diseases. Most of the known 
pressor, proliferative, and profibrotic actions of angiotensin II are 
mediated through its binding to the angiotensin type 1 (AT1) recep-
tor. After the conversion of angiotensinogen to angiotensin I (Ang 
I) in the circulation and tissues, Ang I, through the interaction with 
angiotensin-converting enzyme (ACE) forms angiotensin II, 
whereas additional angiotensin peptides, such as angiotensin-(1-7), 
are generated from either angiotensin I by the action of several 
tissue endopeptidases or the metabolism of angiotensin II by ACE-
2, a newly recognized ACE homologue [46]; the ACE and the 
ACE2 systems will be better elucidated in the next part of this re-
view.  
 Activation of RAAS in hypertensive disease leads to a wide-
spread activation of the inflammatory response mediated by the 
element of the system, mainly by Ang II. Ang II, infact, plays a key 
role in the regulation of the vascular inflammatory response by 
activating the recruitment of inflammatory cells to injured arteries. 
On the other side, inflammatory cells themselves can produce an-
giotensin II, resulting in a local positive feedback response, thereby 
perpetuating the inflammatory cycle (see Fig. 2).  
 One of the main events characterising the early phase of vascu-
lar damage Ang-II mediated in hypertensives is VEGF (Vascular 
Endothelial Growth Factor) over expression. The VEGF family 
(VEGF-A, VEGF-B, VEGF-C, and VEGF-D) has a key role in 
physiological vasculogenesis and has been implicated in pathologic 
angiogenesis, vascular leakage, and inflammation. Angiotensin II 
up-regulates VEGF mRNA expression in vascular and renal cells 
(VSMCs, endothelial cells, cardiac myofibroblasts, mesangial 
cells), primarily through the AT1 receptor. This involvement of 
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Ang II in the early phase of vascular inflammation is mediated in-
dependently of hemodynamic changes [47].  
 Ang II, furthermore, modulates vascular inflammation by regu-
lating the expression of adhesion molecules, chemokines, and cyto-
kines, such as TNF-, IL-6, as well as growth factors and cy-
clooxygenase-2 within the arterial wall, that participate at various 
points in the inflammatory pathway [48]. Ang II also participates in 
the complex processes of leukocyte margination (rolling and adhe-
sion) and diapedesis (transmigration through the vascular wall), 
through the upregulation of several mediators such as selectins, 
integrins, ICAMs, cytokines, and chemokines. Selectins, which are 
lectin-like molecules, are expressed on leukocytes (L-Selectin), 
endothelial cells (E-Selectin, P-Selectin) and platelets (P-Selectin) 
and mediate initial contact between circulating leukocytes and en-
dothelium, manifested as cell rolling [48]. This event promotes the 
adhesion of lymphocytes and monocytes to the endothelial surface, 
thus contributing to the initiation and progression of atherosclerotic 
plaques. Rolling leukocytes encounter activating stimuli which 
promote leukocyte integrins to bind to adhesion molecules, such as 
ICAM-1, ICAM-2, and VCAM-1, required for firm adhesion [49]. 
Recruited cells can produce angiotensin II (intracellular angiotensin 
system), resulting in a positive feedback response, which can main-
tain this inflammatory vicious circle. 
 Ang II also induces vascular injury by increasing the expression 
of MCP-1, which further facilitates the movement of monocytes 
and T cells into the vascular tissue. Ang II infusion in rats upregu-
lates MCP-1 gene expression in renal and vascular cells [50].  
 Besides its direct effects on the inflammatory pathway, Ang II, 
through the binding with AT1 receptor, is also capable of promot-
ing inflammation indirectly via the stimulation of several transcrip-
tion factors, for example, NF-B, that, in turn, regulates production 
of cytokines in several cell types and expression of adhesion mole-
cule (such as VCAM-1 and ICAM-1). [36-39]. In VSMCs (vascular 
smooth muscle cells) Ang II stimulates the production of proin-
flammatory cytokines and chemokines, such as IL-6, IL-8, osteo-
pontin, and MCP-1, which is an important mediator for the direct 
migration of monocytes into the intima. [51].  
 The local effects of Ang II may be mediated in part by the di-
rect pro-inflammatory vascular actions of CRP, because VSMC 
AT1 receptor expression is increased by CRP [52].  
 On the other hand, the RAAS can modulate the activation of 
complement system in both atherosclerosis and renal injury [53].  
 A recent study developed in cultured rat cerebrovascular 
smooth muscle cells confirmed that Ang II stimulated gene expres-
sion of osteopontin, a soluble cytokine that participates in VSMCs 
adhesion and migration [54]. Data from experimental studies indi-
cated that Ang II stimulates the expression of TNF- and IL-6 in 
renal cells and in cardiac fibroblasts [55].  
 In cultured VSMCs, furthermore, Ang II through AT-1 recep-
tor, stimulated hyperplasia and hypertrophy by transactivation of 
epidermal growth factor receptor, platelet derived growth factor, 
and insulin-like growth factor receptor [56]. However, Ang II also 
induced apoptosis of VSMCs mediated by the AT-2 receptor in a 
mouse model of aortic banding-induced hypertension [57].  
 Ang II affects also vascular structure, cell growth, and fibrosis 
which could contribute to vascular remodelling by stimulating hy-
perplasia, hypertrophy, and apoptosis [6]. 
 Arterial hypertension causes a change in vascular wall structure 
involving altered extracellular matrix composition. MMPs (matrix 
metalloproteinases), especially MMP-9, seem to play a key role in 
vascular remodelling from the early stages of hypertensive damage, 
influencing also atherosclerotic lesion progression and plaque in-
stability by their observed action against the stability of the plaque 
and the integrity of fibrous cap: MMPs, infact, can digest the fi-
brous cap and thereby participate in the triggering of plaque rupture 
[58]. In Ang II-induced hypertension, there is increased MMP-9 
activity in conduit vessels. It has been observed that the absence of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Angiotensin II-induced vascular and systemic inflammation (see text) – Modified from [4]. 
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MMP-9 activity results in vessel stiffness, and MMP-9 activation is 
associated with a beneficial role early in hypertension [58].  
 This pro-inflammatory and pro-atherosclerotic effect of Ang II, 
from the early stage of vascular wall inflammation to the end-stage 
of atherosclerotic damage with plaque rupture, is further enhanced 
by the involvement of RAAS in the coagulation cascade. In particu-
lar this hormonal axis inhibits fibrinolysis and enhances thrombosis 
by increasing plasminogen activator-1 production in endothelial and 
vascular smooth muscle cells and by activating platelets [59], im-
pairing the clot formation/clot degradation local balance. Ang II has 
been also shown to increase LDL oxidation in macrophages, 
oxLDL receptor (LOX-1) expression in endothelial cells, superox-
ide and metalloproteinase production, and lipid peroxidation [59].  
 De Ciuceis et al [60] recently reported that osteopetrotic mice 
deficient in mCSF (murine colony-stimulating factor) and accord-
ingly monocytes/macrophages in the vascular wall present less 
oxidative stress and less induction of inflammatory molecule up-
regulation in the vasculature by Ang II, and develop less endothelial 
dysfunction and vascular remodelling, suggesting a central role for 
macrophages and pro-inflammatory mediators in Ang II induced 
vascular injury, linking very close Ang II and macrophagic activa-
tion. In humans, an analysis of both ruptured and hypercellular 
plaques demonstrated high levels of ACE in macrophages. Accord-
ingly, little or no ACE was found in areas with only fibrotic plaques 
[60]. These data suggest that ACE may be associated to atheroscle-
rotic plaque development and vulnerability through the direct regu-
lation of inflammatory cells.  
 The majority of the direct proinflammatory effects induced by 
Ang II are mediated by AT1 receptor. These evidences created the 
plausible belief that AT1 blockers rather than ACEs could exert 
main anti-inflammatory effects interfering exactly with the key 
mediator of RAAS pro-inflammatory and pro-atherosclerotic ef-
fects. Nevertheless the RAAS is really rather complex and a single 
intervention may create only a partial inbalance of the system 
whose consequences are only partly of that expected. AT1 receptor 
itself exert a wide range of actions and a few of these are only 
somewhat investigated.  
 Less is known about AT2 receptors. They are mainly localised 
in cardiac interstitial fibroblasts and are capable of binding not only 
Ang II but also other angiotensins, including angiotensin III. AT2 
receptors also signal through NF-B-mediated pathways but they 
may counterbalance AT1 receptor-mediated effects through the 
activation of phosphatases rather than kinases [61]. AT2 receptor 
pathways increase bradykinin production and NO synthase activity 
in endothelial cells [61]. AT2 receptor activation also inhibits 
growth of cultured vascular smooth muscle cells and cardiac myo-
cytes. On the other hand, the selective AT2 receptor blockade has 
been shown to inhibit in vivo medial smooth muscle hypertrophy 
and fibrosis in hypertensive rats [61]. These controversial results 
suggest that also the role of AT2 receptors is still not clear. 
 We have focused our attention on the effects of Ang II that is 
certainly the main actor of RAAS-mediated vascular inflammation. 
Ang II induces aldosterone synthesis through stimulation of AT1 
(Ang II type 1) receptors in the adrenal cortex. Aldosterone in-
creases tissue ACE (angiotensin converting enzyme) activity and 
up-regulates angiotensin receptors [62], which suggests the exis-
tence of a vicious cycle that may potentiate the effect of the RAAS.  
 Several studies have demonstrated that also aldosterone activa-
tion induces elevation of oxidative stress and vascular inflammation 
[63]. Similar role is demonstrated for mineralcorticoid receptor 
(MR) [63]. Specifically, treatment with aldosterone and salt caused 
extensive inflammatory arterial lesions with perivascular macro-
phages in the rat heart and increased the expression of ICAM, cy-
clooxygenase-2, osteopontin, and MCP-1, effects that were de-
creased by MR blockade [63].  
 The activation of mineralocorticoid receptors (MRs) may con-
tribute to cardiovascular dysfunction, inflammation, fibrosis and 
vascular damage. Several animal models have confirmed that aldos-
terone and other mineralocorticoids can cause injury of the vascula-
ture of the brain, heart and kidneys by inducing ROS formation and 
endothelial dysfunction [63]. Mineralocorticoid antagonism attenu-
ates this damage by mechanisms that appear to be independent of 
changes in BP, involving direct pro-inflammatory and pro-fibrotic 
effects that may involve activation of the ET system [64,65,66,67]. 
Mineralocorticoid receptor blockade also improved endothelial 
function and reduced oxidative stress in Ang II-infused rats [68], 
suggesting that aldosterone induces actions usually attributed to 
direct effects of Ang II. Moreover, aldosterone may induce endo-
thelial dysfunction and inflammation through activation of COX-2 
(cyclo-oxygenase-2) in normotensive and hypertensive rats [69]. 
 MR antagonism also decreases aortic inflammation, fibrosis, 
and hypertrophy in hypertensive rats, as well as oxidative stress and 
inflammation in apolipoprotein E-deficient mice, as indicated by 
TNF- and MCP-1 expression [70]. 
 Furthermore, genetic expression studies in cultured VSMCs and 
cardiomyocytes have confirmed that aldosterone plays a critical 
role in the inflammatory and profibrotic process [71]. 
 Systemic administration of aldosterone increases oxidative 
stress in the rat heart, vasculature, and kidney, which activates the 
redox sensitive NF-B, triggering inflammation [72]. 
 Regarding the in vivo proinflammatory effects of aldosterone, 
studies have focused on the measurement of circulating inflamma-
tory biomarkers such as TNF-, MCP-1, and CRP [73]. 
 Twelve-hour infusion of aldosterone increased IL-6 and IL-12 
concentrations in normal volunteers. Serum levels of IL-6 were 
measured in response to mineralocorticoid stimulation, but the 
available data should be interpreted with caution. Although IL-6 
levels increased, they were below the manufacturer’s recommended 
level of detection. In addition, the amount of IL-6 measured in se-
rum in response to the mineralocorticoid (1.8 pg/mL) probably was 
not biologically significant, as at least 10 pg/mL are necessary in 
most standard bioassay systems. Thus, such data should be consid-
ered more as suggestive of the causal relationship between inflam-
mation and hypertension rather than definitive [74]. 
 Moreover, spironolactone decreased MCP-1 concentration and 
oxidative stress, as measured by urinary F2-isoprostanes, in hyper-
tensive subjects taking hydrochlorothiazide [75]. 
 Although MR antagonists prevent the inflammatory effects of 
aldosterone in most rodent models, studies in cultured VSMCs 
suggest the possibility of an MR-independent proinflammatory 
effect of aldosterone. For example, treatment with spironolactone 
does not block specific molecular pathways that result in the pro-
duction cytokines and chemokines. Obviously, these studies imply 
therapeutic consequences creating new target for drugs and making 
theoretically possible new associations among different classes of 
drugs acting against different targets into RAAS. 
PART III - CHARACTERISTICS OF RENIN ANGIOTENSIN 
ALDOSTERONE SYSTEM AND RAAS-SUPPRESSING 
DRUGS 
RAAS Overview 
 History of RAAS begun in 1898, when Tigerstedt and Bergman 
published an account of their research demonstrating the existence 
of a heat-labile substance in crude extracts of rabbit renal cortex 
that caused a sustained increase in arterial pressure [76]. They pro-
posed the term “renin” for a presumed humoral pressor agent se-
creted by the kidney, a concept that was widely disputed or ignored 
until the classical studies of Goldblatt and colleagues, published in 
1934, that showed that renal ischemia induced by clamping of the 
renal artery could induce hypertension [77]. Shortly thereafter it 
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was shown that the ischemic kidney also released a heat-stable, 
short-lived pressor substance, in addition to renin. This finding 
eventually led to the recognition that renin’s pressor activity was 
indirect and resulted from its proteolytic action on a plasma sub-
strate (eventually termed “angiotensinogen”) to liberate a direct-
acting pressor peptide. This peptide was initially termed “an-
giotonin” or “hypertensin” by competing investigators in the United 
States (Page and colleagues) and in Argentina (Braun-Menendez 
and colleagues), who ultimately compromised on the term “angio-
tensin” [77]. 
 Later, in the 1950s two different peptides of angiotensin were 
discovered and a plasma enzyme, termed “angiotensin-converting 
enzyme,” able to generate the active pressor peptide Ang II, was 
identifitied. Soon after, the work of several scientists led to the 
acquisition of Ang II activity on adrenal cortex, stimulating the 
release of a hormone, called aldosterone, having main biological 
role as a regulator of sodium and potassium balance. 
 Decades of researches led to the knowledge of RAAS we have 
today (see Fig. 3), and nevertheless the identification of several 
components of the system, the role of many of these especially in 
specific areas such as inflammation are still unclear. 
 Renin is synthesised as a pre-hormone and stored in granules in 
the juxtaglomerular cells (JG), close to the afferent (and occasion-
ally efferent) arteriole of the renal glomerulus. Release of renin 
from JG cells into blood flow is dependent on least at four different 
stimuli: (1) a renal baroreceptor mechanism in the afferent arteriole 
that senses changes in renal perfusion pressure, (2) changes in de-
livery of NaCl (sensed as changes in Cl- concentration) to the mac-
ula densa cells of the distal tubule (which lie close to the JG cells 
and, together, form the “JG apparatus”), (3) sympathetic nerve 
stimulation via beta-1 adrenergic receptors, and (4) negative feed-
back by a direct action of Ang II on the JG cells [78]. 
So, main factors conditioning renin secretion are the JG stimulation 
by a fall in perfusion pressure or in NaCl delivery and by an in-
crease in sympathetic activity.  
 Renin is also synthesized in other tissues, including brain, adre-
nal gland, ovary, and visceral adipose tissue, and perhaps heart and 
vascular tissue. The factors regulating synthesis and possible ac-
tions of renin in these other tissues are poorly understood. Control 
of renin secretion is a key determinant of the activity of the RAAS. 
 Renin regulates the initial step of the RAAS by cleaving the N-
terminal portion of a large molecular weight globulin, angiotensi-
nogen, to form the biologically inert decapeptide Ang I or Ang-(1-
10), The primary source of systemic circulating angiotensinogen is 
the liver, but angiotensinogen mRNA expression has also been 
detected in many other tissues, including kidney, brain, heart, vas-
cular, adrenal gland, ovary, placenta, and adipose tissue [79]. 
 Angiotensinogen is secreted constitutively by the liver, so 
plasma levels are generally stable and do not change acutely; how-
ever, both hepatic and extrahepatic synthesis have been shown to 
rise in response to glucocorticoids, estrogens and other sex steroids, 
thyroid hormone, inflammatory cytokines (e.g., interleukin-1 and 
tumour necrosis factor), and Ang II [79]. 
 The inactive decapeptide Ang I is hydrolysed by angiotensin- 
converting enzyme (ACE), which removes the C-terminal dipeptide 
to form the octapeptide Ang II [Ang-(1-8)], a biologically active, 
potent vasoconstrictor. ACE is a membrane-bound exopeptidase 
and is localised on the plasma membranes of various cell types, 
including vascular endothelial cells, microvillar brush border 
epithelial cells (e.g., renal proximal tubule cells), and neuroepithe-
lial cells. It is this membrane-bound ACE that is thought to be 
physiologically important. ACE also exists in a soluble form in 
plasma, but this form may simply reflect turnover and clearance of 
membrane-bound ACE. ACE (also known as kininase II) metabo-
lizes a number of other peptides, including the vasodilator peptides 
bradykinin and kallidin, to inactive metabolites [80]. Thus, func-
tionally, the enzymatic actions of ACE potentially result in in-
creased vasoconstriction and decreased vasodilation. 
 Although Ang II is the primary active product of the RAAS, 
there is evidence that other metabolites of Ang I and II may have 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Scheme of Renin-Angiotensin-Aldosterone System (RAAS). 
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significant biological activity, particularly in tissues. Ang III and IV 
are formed by the sequential removal of amino acids from the N-
terminus of Ang II by the action of aminopeptidases. 
 Ang III [Ang-(2-8)], a heptapeptide formed by removal of the 
first N-terminal amino acid, is present in the central nervous system 
(CNS), where it is thought to play an important role in tonic blood 
pressure maintenance and in hypertension [81]. Ang IV [Ang-(3-8)] 
is a hexapeptide formed by further enzymatic degradation of Ang 
III [81]. Preclinical studies have suggested a cooperative effect of 
Ang IV in Ang II signalling. For instance, it appears that in the 
brain, Ang IV increases blood pressure by cooperating with Ang II 
on angiotensin II type 1 (AT1)-receptor signalling, because its 
hemodynamic effects require the presence of both Ang II and func-
tional AT1 receptors [81]. 
 Peptides truncated at the C-terminus of Ang II may also have 
biological activity. For example, Ang-(1-7), a heptapeptide frag-
ment of Ang II, can be formed from Ang I or Ang II by the actions 
of several endopeptidases or from Ang II by the action of car-
boxypeptidases, including one with significant structural homology 
to ACE (which has been termed “ACE 2”). Unlike ACE, this en-
zyme does not convert Ang I to Ang II and its activity and Ang-(1-
7) levels are not affected by ACE inhibitors (ACEIs) and ARBs 
[46,80].  
 Ang-(1-7), which seems to act via a unique receptor, was first 
described to have vasodilatory effects and act as a natural ACEi, 
acting as a modulator of the RAAS [46,81]. So, ACE2 activity and 
Ang-(1-7) may counterbalance the activity of the ACE-mediated 
way, whose blockage is actually a therapeutical target. ACE 2 and 
Ang-(1-7) appear to be upregulated by ACEis use mainly in myo-
cardium and kidney. Cardioprotective effects have been proposed to 
result from a direct effect of Ang-(1-7) on heart cells or a general-
ised systemic effect, [46,81] but evidence for such actions in human 
studies is lacking. ACE 2 is also highly expressed in hypothalamus 
and aorta. ACE 2 can also cleave a single amino acid from the C-
terminus of Ang I to form Ang-(1-9), a peptide with no known 
function at this time. 
 As already noted, Ang II is the primary effector of a variety of 
RAAS-induced physiological and pathophysiological actions. 
These biological effects are mediated by specific receptors: at least 
4 angiotensin receptor subtypes have been described [82].  
 The type 1 (AT1) receptor mediates most of the established 
physiological effects of Ang II (see Figs. 3 and 4). These include 
actions on the cardiovascular system (vasoconstriction, increased 
blood pressure, increased cardiac contractility, vascular and cardiac 
hypertrophy), kidney (renal tubular sodium reabsorption, inhibition 
of renin release), sympathetic nervous system, and adrenal cortex 
(stimulation of aldosterone synthesis), but also mediate the pro-
inflammatory effects, the effects on cell growth and proliferation 
and, finally ROS production and oxidative stress [80].  
 This receptor, which is typical of the G protein-coupled recep-
tor superfamily containing 7 membrane-spanning sequences, is 
widely distributed on many cell types in Ang II target organs. 
 The type 2 (AT2) receptors are ubiquitously expressed during 
fetal life in the brain, kidney, and other sites, and its levels decrease 
markedly in the first few hours after birth. There is some evidence 
that, despite low levels of expression in the adult, the AT2 receptor 
might mediate vasodilation and antiproliferative and apoptotic ef-
fects in vascular smooth muscle and inhibit growth and remodelling 
in the heart [80,82]. In the kidney, it has been proposed that activa-
tion of AT2 receptors may influence proximal tubule sodium reab-
sorption and stimulate the conversion of renal prostaglandin E2 to 
prostaglandin F2 [80]. However, the importance of any of these 
AT2-mediated actions remains uncertain. 
 The type 4 (AT4) receptors are thought to mediate the release 
of plasminogen activator inhibitor 1 by Ang II and by the N-
terminal truncated peptides (Ang III and Ang IV), but the function 
of the type 3 (AT3) receptors is unknown [82]. Lastly, the putative 
effects attributed to the C-terminal truncated peptide Ang 1-7, in-
cluding vasodilatation, natriuresis, antiproliferation, and cardiac 
protection, are presumed to be mediated by a unique receptor that 
does not bind Ang II, most likely a product of the Mas proto-
oncogene known as the Mas receptor [82].  
 In addition to receptors for the angiotensin peptides, very recent 
evidence suggests the existence of high-affinity cell surface recep-
tors that bind both renin and prorenin in several tissues, including 
heart, brain, placenta, and kidney, with localization to glomerular 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Differential location and functions of type AT1 and AT2 Angiotensin receptors. 
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mesangium and subendothelial vascular smooth muscle [83]. One 
receptor that has been carefully characterised has been reported to 
cause reversible activation of bound prorenin and to enhance the 
catalytic activity of bound renin, thus serving as a template for local 
Ang I generation. The receptor also has been reported to initiate 
intracellular signalling, independent of Ang peptide synthesis, lead-
ing to activation of mitogen-activated protein kinases ERK1 and 
ERK2 [83].  
 As previously described, Ang II, via the AT1 receptor, also 
stimulates the production of aldosterone by the zona glomerulosa, 
the outermost zone of the adrenal cortex. Aldosterone is a major 
regulator of sodium and potassium balance and thus plays a major 
role in regulating extracellular volume. It enhances the reabsorption 
of sodium and water in the distal tubules and collecting ducts (as 
well as in the colon and salivary and sweat glands) and thereby 
promotes potassium (and hydrogen ion) excretion [84]. Ang II, 
together with extracellular potassium levels, are the major regula-
tors of aldosterone, but Ang II synthesis may also be stimulated by 
adrenocorticotrophic hormone (ACTH; corticotropin), norepineph-
rine, endothelin, and serotonin and inhibited by atrial natriuretic 
peptide and nitric oxide (NO). It is also important to note that Ang 
II is a major trophic factor for the zona glomerulosa, which can 
manifest atrophy (reversibly) in its absence. 
 Recently, growing evidences are accumulated regarding the 
concept that the RAAS functions both as a circulating system and 
as a tissue paracrine/autocrine system [80].  
 This important new acquisition about RAAS physiology origi-
nates from the evidence that angiotensin synthesis, such as recepto-
rial ad signal transduction pathways may be found in several tissues 
as well as in the circulation.  
 There is evidence that local or “tissue” Ang II biosynthesis may 
be initiated by renin and/or angiotensinogen taken up from the cir-
culation. In addition, independent Ang II generating systems have 
been postulated to exist in the heart, peripheral blood vessels, kid-
ney, brain, adrenal glands, pituitary, adipose tissue, testes, ovaries, 
and skin [80].  
 Serine proteases, including several kallikrein-like enzymes 
(tonins), cathepsin G, and chymase are thought to contribute to Ang 
II formation in the tissue RAAS [85]. Studies have suggested that 
non-ACE pathways are, by inference, responsible for about 40% of 
Ang II generation in the intact human kidney [86] and that chymase 
is the dominant Ang II-generating pathway in the human heart, 
coronary arteries, and atherosclerotic aorta in vitro [85,87,88]. It 
has thus been proposed that abnormal activation of the tissue RAAS 
may contribute to the pathogenesis of cardiovascular disease even 
in the absence of derangements in the circulating system [89]. It 
must be considered that the greatest part of the evidences regarding 
the “tissue” RAAS” obtained in vitro, so not necessarily in vivo 
mechanisms may be similar or have the same pathophysiological 
and thus clinical relevance. More specific studies are needed to 
explore this particular subject. 
 Although these local-synthesized RAAS components are as-
sumed to accomplish similar function of systemic one, different 
local tissue not necessarily has the same behaviour. For example 
cardiac RAAS, under physiological conditions, exerts the apparent 
function to maintain cellular balance of inhibiting and inducing cell 
growth, and proliferation and mediation of adaptive responses to 
myocardial stretch [90]. The majority of Ang II in cardiac tissue 
appears to be produced by local synthesis of Ang I and subsequent 
local conversion to Ang II, rather than from uptake of peptides from 
the systemic circulation [80]. Although it has been suggested that 
locally synthesised renin and/or additional proteolytic enzymes may 
be involved in this synthetic process, current evidence favours the 
concept that circulating renin and angiotensinogen, which are able 
to pass through the endothelial barrier, are taken up by cardiac tis-
sue where they act locally [91]. Ang II exerts an inotropic effect (at 
least in atrial preparations), mediates myocyte hypertrophy via the 
AT1 receptor, and is involved in cardiac remodelling [91]. Patho-
logic activation of cardiac RAAS, perhaps through local upregula-
tion of ACE levels, has been proposed to contribute to the devel-
opment and maintenance of left ventricular hypertrophy [89].  
 VSMCs, endothelial, and endocardial cells generate Ang I and 
Ang II, again apparently via the uptake of circulating renin [80]. It 
has been suggested that the vascular RAAS contributes to the main-
tenance of cardiovascular homeostasis through its effects on both 
AT1 and AT2 receptors and mediates long-term effects on vascular 
remodeling by stimulating proliferation of vascular smooth muscle 
cells and fibroblasts [90]. 
 Endothelial dysfunction is associated with upregulation of local 
tissue ACE, which might contribute to disrupting the balance of 
vasodilation and vasoconstriction. Vascular local ACE hyperfunc-
tion leads also to several Ang II mediated pro-inflammatory effects.  
 The kidney is one of the districts where RAAS activity exerts 
more pathophysiological actions, and in which hyperactivity of the 
system and iperproduction of Ang II and aldosterone cause more 
changes of glomerular filtration and kidney-mediated idro-
electrolitic balance. 
 The intrarenal RAAS may explain the primary role of Ang II as 
a paracrine substance in the control of renal function. The direct 
intrarenal actions of Ang II include renal vasoconstriction, tubular 
sodium reabsorption, sensitivity of tubuloglomerular feedback, 
modulation of pressure-natriuresis, and promotion of renal tissue 
growth [90]. Under normal conditions, Ang II constricts both the 
afferent and efferent arterioles and stimulates mesangial cell con-
traction, which results in reduced renal blood flow, glomerular fil-
tration rate (GFR), and filtered sodium load [80]. 
 On the other hand, overactivation of the intrarenal RAAS may 
thus contribute to the pathophysiology of sodium-retaining states, 
such as hypertension and congestive heart failure (CHF). On the 
other hand, in conditions characterized by severe impairment of 
renal perfusion, such as renal artery stenosis, the afferent circula-
tion, which is dilated as a result of autoregulation, is relatively re-
fractory to the constrictive actions of Ang II, and the predominant 
constriction of efferent arterioles by Ang II plays a major role in 
maintaining glomerular perfusion pressure and, thus, GFR. 
 Due to the presence of the blood-brain barrier, the brain is 
largely isolated from the circulating RAAS; therefore, local Ang II 
synthesis by a brain RAAS has been proposed to play a role in cen-
tral blood pressure regulation [90]. 
 Local brain effects of RAAS overactivation in hypertesive rats 
have been found through Increasing in brain renin activity, renin 
and angiotensinogen mRNA, and detectable numbers of AT1- and 
AT2-receptor subtypes [90].  
 The existence of a relationship between systemic blood pressure 
levels and brain RAAS function has been confirmed by data show-
ing that the modulation of brain AT1- and AT2-receptors has been 
shown to lower blood pressure in hypertensive rats [92] and regard-
ing the hypotensive effects of administration of Ang II into the 
brain. These effects would be the result of the combined systemic 
effects of vasopressin release, sympathetic nervous system activa-
tion, and inhibition of baroreflexes. [92]. 
 Adrenal glands seems able to produce renin, and consequently 
Ang II, in a kidney-independent way [93]. All components of the 
RAAS are present in adrenal cortex and comprise the adrenal 
RAAS. Renin and angiotensinogen mRNA have been identified in 
the adrenal gland, and Ang II formation has been demonstrated in 
zona glomerulosa cells.7 Most (90%) adrenal renin activity has 
been localized to the zona glomerulosa, [93] and more than 90% of 
adrenal Ang II originates at local tissue sites. [94] In transgenic 
animal models it has been shown that sodium restriction can in-
crease adrenal renin and aldosterone independently of plasma or 
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kidney renin concentrations. Additionally, bilateral nephrectomy, 
which decreases cardiac and vascular renin, does not decrease adre-
nal renin in experimental animals [95]. It is not known if the adre-
nal RAAS functions as a paracrine or autocrine system or if it has a 
pathophysiological role, and the relative importance of systemic 
versus locally synthesized Ang II in the control of adrenal function 
is uncertain.  
Main Characteristics of RAAS-suppressing Drugs 
 Angiotensin-Converting Enzyme Inhibitors (ACE-i). Early 
attempts to block ACE in order to obtain pharmacological advan-
tages date from 1960s [77]. Studies conducted on the peptides de-
rived from the venom of the Brazilian arrowhead viper (Bothrops 
jararaca) showed inhibition of kinase II, an enzyme that facilitates 
degradation of bradykinin, and which was later shown to be identi-
cal to ACE. Synthetic analogues of the peptide fraction of snake 
venom, such as the nonapeptide teprotide, were shown to lower 
blood pressure in patients with hypertension and produce beneficial 
hemodynamic effects in patients with heart failure [77]. These find-
ings encouraged the search for orally active inhibitors of ACE; the 
first of these, captopril, was designed based on known inhibitors of 
another zinc-containing metalloprotease, carboxypeptidase A, and 
included a sulfhydryl-containing amino acid to serve as ligand for 
the zinc moiety. Because many of the side effects of captopril, such 
as proteinuria, skin rashes, and altered taste, were attributed to the 
sulfhydryl group, subsequent work led to the development of 
ACEIs that replaced this group with a carboxyl group (e.g., lisino-
pril, benazepril, quinapril, ramipril, perindopril, cilazapril, trando-
lapril) or phosphoryl group (fosinopril) [96,97]. The presence of the 
carboxyl group conferred greater lipophilicity, which actually im-
proved binding to ACE, and improved tissue penetration [97]. 
ACEIs competitively block the action of ACE and thus the conver-
sion of Ang I to Ang II, thereby reducing circulating and local lev-
els of Ang II. ACEIs also decrease aldosterone and vasopressin 
secretion and sympathetic nerve activity, but there is controversy 
regarding their efficacy in blocking other “tissue” actions of the 
RAAS [98]. Short-term ACEI therapy is associated with a decrease 
in Ang II and aldosterone and an increase in renin release and Ang 
I. There is some evidence, however, that over the long term ACE 
inhibition may be associated with a return of Ang II and aldosterone 
toward baseline levels (“ACE escape”) perhaps through activation 
of alternate pathways [98,99]. The extent of the ACE escape phe-
nomenon has been largely discussed, especially after the introduc-
tion of ARBs that theoretically may overcome this problem, certain 
is that because ACEIs are all competitive inhibitors of the enzyme, 
it is likely that increased levels of Ang I (provoked by the compen-
satory increase in PRA due to loss of negative feedback inhibition) 
can tend to partially overcome the blockade [100]. This event 
would be especially magnified in high-renin or volume-depleted 
patients with a particularly robust reactive rise in PRA. ACE-is are 
generally well-tollerated drugs by most patients. The most frequent 
side effects are dry cough, which has been attributed to accumula-
tion of substance P (which is normally degraded by kininase II). 
 In general, short-term pharmacodynamic responses to decreases 
in Ang II through inhibition of ACE include dose-dependent reduc-
tions in cardiac preload and afterload, with lowering of systolic and 
diastolic blood pressure, although in normotensive and hypertensive 
patients without cardiac dysfunction, little or no change in cardiac 
output or capillary wedge pressure are seen. 
 Of note, unlike direct-acting arterial vasodilators, ACEI-
induced reductions in total peripheral vascular resistance occur 
without a significant change in heart rate [98]. ACEIs also decrease 
renal vascular resistance, increase renal blood flow, and promote 
sodium and water excretion. Mainly through cellular effects in the 
kidney and through alterations in glomerular hemodynamics, 
ACEIs also may prevent the progression of microalbuminuria to 
proteinuria, reduce proteinuria in patients with established glomeru-
lar disease, and prevent or delay the progression of renal insuffi-
ciency to end-stage renal disease. Efficacy in long-term trials has 
been demonstrated particularly in patients with nondiabetic neph-
ropathies or in patients with insulin-dependent (type 1) diabetes. 
[98,101,102]. 
 The analysis of the cardiovascular effects of ACE-is administra-
tion is not the aim of this review, but several data should be noted. 
In 40% to 60% of patients with mild-to-moderate hypertension, 
ACEI monotherapy produces a satisfactory reduction in blood pres-
sure; in this population, ACEIs contribute to reversal of cardiac 
hypertrophy. In patients with CHF, ACEIs relieve pulmonary con-
gestion by a balanced reduction in cardiac preload and afterload, 
through various vascular mechanisms [103]. ACEIs have also been 
shown to improve endothelial dysfunction in patients with heart 
failure, as well as in patients with coronary artery disease and type 
2 diabetes [98,104]. 
 In early landmark trials in patients with CHF (such as CON-
SENSUS, SOLVD, and V-HeFT-II), ACEIs were shown not only 
to markedly improve symptoms and functional status, but also to 
dramatically reduce mortality. In subsequent studies in patients who 
have suffered a myocardial infarction (MI), such as SAVE, AIRE, 
and TRACE, ACEI therapy has been shown to prevent or retard 
ventricular remodeling and progression to CHF, and thereby to 
reduce overall mortality and prolong survival [105-112]. 
 Furthermore, results of the HOPE trial and other smaller studies 
indicate broad cardiovascular benefits of ACEi therapy in “high-
risk” patients (including both hypertensive and normotensive indi-
viduals), and it is possible that these benefits occur in part inde-
pendently of their blood pressure-lowering effect [112]. 
 Several large-scale studies of various ACEIs have shown a 
reduction in incidence of new-onset diabetes in association with 
ACEI therapy. For example, this has been shown with captopril in 
patients with hypertension (CAPP), [113] with ramipril in patients 
at high risk for cardiovascular disease (HOPE), [112] with enalapril 
in patients with left ventricular dysfunction (SOLVD), [114] and 
with trandolapril in patients with stable coronary disease (PEACE) 
[115]. The mechanisms of this benefit has not been determined but 
open the door to the ancillary effects of RAAS-suppressing drugs, 
to the achieved health benefits beyond BP levels reduction and 
hypothesize a further enlargement of ACEi clinical indications. All 
these issues will find further emphasis after the beginning of ARBs 
era.  
 Angiotensin Receptor Blockers (ARBs) development fol-
lowed the discovery of the different types of Ang II receptors and 
the knowledge of the AT1 receptors role in cardiovascular pathol-
ogy. Development of orally active, nonpeptide, selective AT1 re-
ceptor blockers began in the 1990s with the synthesis of losartan 
[77]. Since 1995, when losartan was granted approval as an anti-
hypertensive, a total of seven ARBs have been synthesized and 
approved, including valsartan, irbesartan, candesartan, eprosartan, 
telmisartan, and olmesartan. All these ARBs are actually indicated 
for anti-hypertensive treatment; in some case acquisition of the 
results of several RCT performed in these years, entailed additional 
indications (see Table 1).  
 Because ARBs act by blocking Ang II action at the receptor 
level, rather than by inhibiting its synthesis, they ought to antago-
nize AT1-mediated effects of Ang II no matter how it is synthe-
sized. In other words, if there were significant Ang II synthesis in 
tissues by alternate pathways, such as chymase in the heart, this 
would limit the efficacy of ACEIs (but not of ARBs) through a 
mechanism postulated to contribute to the “escape” phenomenon 
following long-term ACE inhibition. [116] In contrast to the 
ACEIs, ARB therapy actually results in an increase in Ang II levels 
[117]. As with ACE inhibition, blockade of the AT1 receptor inhib-
its the negative feedback loop, leading to increased renin secretion 
and thus to increased synthesis of Ang I. In the case of ARBs, the 
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increase in Ang I lead to a commensurate increase in Ang II, which 
is freely able to bind to AT2 or other receptor subtypes. Earlier 
preclinical studies have suggested that beyond AT1 receptor block-
ade, activation of the AT2 receptor might mediate additional bene-
ficial actions on the vasculature, heart, and kidneys, in part via a 
bradykinin/NO/ cGMP pathway, an effect that would further distin-
guish ARBs from ACEIs. [80].  
 Like the ACEIs, ARBs reduce blood pressure by decreasing 
systemic vascular resistance; they do not affect heart rate and have 
minimal effect on cardiac output in the nonfailing heart [117]. Re-
duced systemic vascular resistance results from a combination of 
inhibition of Ang II-mediated vasoconstriction, reduced sympa-
thetic nervous system activity, and reduced extracellular volume 
(i.e., by direct inhibition of proximal sodium reabsorption and by 
inhibition of aldosterone release) [117]. 
 ARB monotherapy produces a satisfactory reduction in blood 
pressure in 40% to 60% of patients with mild-to-moderate hyper-
tension [118,119]. A number of meta-analyses have calculated risk 
reductions for the ARB class of agents in areas outside of hyperten-
sion and, when taken together, suggest favourable effects in terms 
of preventing stroke and improving renal function and left ventricu-
lar (LV) mass, an uncertain risk/benefit profile in LV dysfunction 
and HF, and a potential increased risk for myocardial infarction 
(MI) in non-HF patients [120-127]. 
 Although conducting meta-analyses that capture multiple agents 
within a drug class is a common practice (with a tendency to also 
group data across ARBs and ACEIs to assess the broader RAAS 
inhibitor category) and may yield clinically interesting information, 
the results and conclusions should not be interpreted as implying an 
overall class effect. In the case of the ARBs, important differences 
exist across the pharmacologic and pharmacokinetic profiles of the 
individual agents, including their binding affinity and selectivity for 
the angiotensin II type 1 receptor (AT1) [128]. When given at their 
highest recommended doses for the treatment of hypertension, 
differences in BP lowering have been described [129]. Clinically, 
the extent to which the AT1 binding affinity/selectivity-related 
extent to which the AT1 binding affinity/selectivity-related differ-
ences within the ARB class influence BP control or long-term car-
diorenal morbidity/ mortality is unknown [128]. 
 The vast RCT experiences during which ARB-associated ef-
fects on outcomes beyond BP control have been compared with 
those for non-ARB agents are captured in Table 2 [129-212]. 
 Potential anti-inflammatory effects of ARBs, with respect to the 
differences emerged among the molecules of the class, have been 
tested in some of the cited RCT and in other more specific analysis 
aimed to address this issue obtaining encouraging results, as 
showed afterwards.  
 The most recent class of agents that block the RAAS to be in-
troduced is the direct renin inhibitors represented by aliskiren [213], 
which was recently approved for treatment of hypertension. This 
compound differs from the ACEIs and ARBs in that, by blocking 
the catalytic activity of renin at the point of activation of the RAAS, 
it blocks the synthesis of all angiotensin peptides and prevents the 
compensatory increase in renin activity. Renin activity and biologi-
cal effects will not be reviewed here. 
PART IV - ANTI-INFLAMMATORY EFFECTS OF ACE-I 
 An emerging awareness of the link between RAAS and in-
flammation has increased the development of theories about the 
anti-inflammatory activities of ACE inhibitors and ARBs as media-
tors of cardiovascular benefits. Given the pro-inflammatory effects 
of Ang II and aldosterone, agents that interfere with the components 
of RAAS, such as ACE inhibitors, ARBs and mineralocorticoid 
receptor antagonists (spironolactone or the more selective epler-
enone), represent logical therapeutic tools to reduce vascular in-
flammation and cardiovascular risk, as suggested in large clinical 
trials in patients with hypertension and diabetes.  
 However, BP reduction by itself may also influence inflamma-
tion, since calcium channel blockers not only decreased BP in pa-
tients with hypertension, but also reduced plasma concentrations of 
ICAM-1, E-selectin and vWF [214]. But nevertheless these reports, 
Table 1. Main Clinical Indications for the Angiotensin Receptor Blockers  
Molecule  Essential Hypertension  Cardiovascular Prevention  Congestive  
Heart Failure  
Diabetic  
Nephropathy  
LOSARTAN     
Stroke risk reduction in hyper-
tensives with left ventricular 
hypertrophy  
    
VALSARTAN     
Post-myocardial infarction  
   
CANDESARTAN       
IRBESARTAN       
TELMISARTAN     
Post-stroke, Post-myocardial 
infarction, Type 2 diabetes 
mellitus  
  
OLMESARTAN      
EPROSARTAN      
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the comparison between drugs with and without efficacy on RAAS 
performed in several trials frequently showed clinical benefits of 
RAAS-suppressing agents beyond those attributable to blood pres-
sure-reducing efficacy alone. 
 Nevertheless ACE inhibitors and ARBs are drugs acting on 
different levels of the same metabolic system, differences between 
the two classes are relevant, both in anti-hypertensive efficacy and 
in ancillary effects. Referring to the relationship between the two 
classes of drugs and inflammation, the evidences supporting an 
anti-inflammatory effect of ACE-i or in the main a significance 
influence of this class of drugs on systemic inflammatory parame-
ters are rather week. Nevertheless this, several studies investigated 
the effects of ACE inhibitors on systemic and vascular inflamma-
tory process and tried to analyse the effects of ACE-i administra-
tions on inflammatory markers such as CRP, cytokines, chemo-
kynes, adhesion molecules and more. 
 Early experimental models indicated that ACEis exert an antia-
therosclerotic effect as there was a relative decrease in cellularity 
and increase in extracellular matrix in aortic atherosclerotic lesions 
of hyperlipidemic rabbits [215]. The crucial role of the RAAS in 
inflammatory processes regulating atherosclerosis was also ob-
served in other animal models prone to develop atherosclerosis. 
One of the most used models was the “stroke-prone” strain (SHR-
SP) rats. Cardiac tissue of hypertensive stroke-prone rats treated 
with high doses of ramipril had no evidence of degeneration, loss of 
structural proteins, or inflammatory infiltrates. Also, ramipril pre-
vented deposition of extracellular matrix proteins and myocyte 
hypertrophy and, finally, decreased mortality [216]. These results 
strongly suggested that ACE inhibitors reduce cardiovascular risk 
and atherosclerosis in animals in different stages of cardiovascular 
disease. These benefits were confirmed by the majority of the 
following published studies using similar murin models. 
Table 2. Main randomized controlled trials that have been evaluated angiotensin receptor blockers vs other treatments for other 
relevant outcomes than blood pressure lowering effect (in boldface are printed the study achieved its primary or secondary 
endpoint(s); roman type designates that study did not meet its primary or secondary endpoint(s) ). 
  Losartan Valsartan Candesartan Irbesartan Telmisartan Eprosartan Olmesartan 
Atherosclerosis Uchiyama-Tanaka Y et 
al, Flammer AJ et al, 
Ichihara A et al, Park 
JB et al, Rehman A et 
al [130-134].  
MARVAL-2, VIP 
[148,149] 
CENTRO, 
MITEC 
[167,119] 
SILVHIA, 
EPAS, ISLAND 
[183-185] 
Asmar R et al,  Jung AD 
et al 
[195,196] 
Leu HB et al 
[206] 
EUTOPIA 
[207] 
Hypertensive left ventricular 
hypertrophy 
LIFE Study [135-138] Anan F et al, 
Cuocolo A et al, 
Thürmann PA et al, 
Yasunari K et al 
[150-153] 
CATCH, 
CASE-J 
[168,169] 
SILVHIA, 
CVIP 
[186-188] 
ONTARGET/ 
TRANSCEND 
[197] 
Diamond JA et 
al 
[208] 
Rosendorff C et al 
[209] 
Secondary prevention post-
myocardial infarction 
OPTIMAAL [139] T-VENTURE, 
VALIANT 
[154-156] 
E-COST 
[170] 
        
Stroke LIFE Study [135,140] JiKei Heart Study, 
KYOTO HEART 
Study 
[157,158] 
SCOPE,  
E-COST * 
[170-172] 
 
  TRAN-
SCEND,PROFESS 
[198,199] 
MOSES 
[210] 
  
Heart Failure ELITE/ELITE II [141-
143] 
  
Val-HeFT 
[159,160] 
RESOLVD, 
CHARM 
[173-180] 
I-PRESERVE 
[189] 
REPLACE 
[200] 
ADEPT 
[211] 
  
Atrial Fibrillation LIFE Study [144] GISSI-AF,  
Val-HeFT 
[161,162] 
CAPRAF 
[181] 
Guntekin U et al, 
Madrid AH et al 
[190,191] 
Celik T et al 
[201] 
    
Protection against renal dam-
age 
RENAAL, JLIGHT, 
ROAD [145,147]  
VALERIA, 
SMART, 
HKVIN, MAR-
VAL, 
MARVAL-2 
[148,163-166] 
DIRECT, 
CENTRO 
[167,182] 
IRMA-2, IDNT, 
IMPROVE 
[192-194] 
INNOVATION, 
TRANSCEND, 
ONTARGET, 
DETAIL 
[202-205] 
  ROADMAP 
[212] 
this table is a summary of fully published randomized controlled trial data, with an emphasis on large-scale trials (when available). Additional smaller studies 
were considered in the absence of data from large-scale clinical trials. 
* E-COST Study achieved end-point prevention of stroke only in secondary prevention, not in primary 
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 Very recently, further data about the effects of captopril ad-
ministration on rat, linked the anti-inflammatory effects of the 
ACEi with NF-B inactivation [217]. Left ventricle mRNA expres-
sion and plasma levels of pro-inflammatory (interleukin-1beta (IL-
1beta) and IL-6) and anti-inflammatory (IL-10) cytokines, were 
measured in spontaneously hypertensive rats (SHR) and their con-
trol normotensive, Wistar-Kyoto (WKY) rats, with or without a 12-
week treatment with captopril (80 mg/Kg/day; n = six animals per 
group) In SHR, the observed increases in blood pressures, heart 
rate, left ventricle relative weight, plasma levels and cardiac mRNA 
expression of IL-1beta and IL-6, as well as the reductions in the 
plasma levels and in the cardiac mRNA expression of IL-10, were 
reversed after the treatment with captopril. Finally, SHR presented 
an elevated cardiac mRNA expression and activation of the tran-
scription nuclear factor, NF-B, accompanied by a reduced expres-
sion of its inhibitor, I-B; captopril administration corrected the 
observed changes in all these parameters. 
 An elegant study comparing the effects of the ACEi enalapril 
and the ARB losartan evaluating in vivo and in vitro data on cell 
injury and temporal association of leukocyte endothelial interaction 
in response to ischemia-reperfusion date 2000 [218]. The extent and 
temporal correlation of cellular damage (propidium-iodide stain-
ing), microvascular perfusion failure and leukocyte-endothelial 
interaction (leukocyte adherence) were investigated by means of 
intravital microscopy, after the application of hemodynamically 
ineffective doses of enalapril and losartan (5 mg/kg). A hamster 
dorsal skinfold model with a 4-h tourniquet ischemia was used. In 
vitro, the effect of enalapril and losartan on polymorphonuclear cell 
(PMN) adherence, as well as adhesion molecule expression (ICAM-
1, VCAM-1), on hypoxia- or IL-1beta-stimulated endothelial cells 
(HUVEC) was assessed using a PMN-adhesion assay and flow 
cytometry, respectively. Enalapril significantly reduced early cellu-
lar damage, microvascular perfusion failure, and leukocyte adher-
ence in response to ischemia-reperfusion. Conversely, AT1 receptor 
inhibition with losartan proved to be ineffective at attenuating 
postischemic microcirculatory disorders (leukocyte-endothelial 
interactions, microvascular perfusion failure) and aggravated cellu-
lar injury. In vitro, enalapril reduced PMN adherence and ICAM-1 
and VCAM-1 expression, while losartan was ineffective in the 
same respect. Following ischemia-reperfusion injury, ACE- versus 
AT1-receptor inhibition induces differential effects concerning the 
extent and temporal association of cell injury and leukocyte-
endothelial interaction. In this study the use of enalapril seems to 
combine the beneficial effects of preventing cell and vascular injury 
immediately after reperfusion, with a delayed inhibition of the in-
flammatory response. Since the AT1-receptor inhibitor losartan did 
not mimic effects obtained with ACE inhibition, it is conceivable 
that the responses in ischemia-reperfusion are mediated by a non-
angiotensin II-AT1 receptor-dependent mechanism. So, in this spe-
cific topic, blocking of AT1 receptor do not provide benefit, al-
though in vivo studies conducted in assets in which RAAS activa-
tion is associated to high cardiovascular risk, searching for more 
clinical aims provides different results as showed afterwards. 
 These encouraging results provided by ACEis in animal model 
clearly suggested to test the hypothesis that also in human models 
interference with RAAS may block the pathophysiological cascade 
leading from cardiovascular risk factors to endothelial dysfunction, 
pre-clinical and clinical atherosclerosis, organ damage and, finally 
major vascular events (CAD, stroke). The main available data re-
garding the supposed anti-inflammatory role of ACEis are shown in 
Table 3. 
 Early data about the role of ACEi quinapril in the reversal of 
the endothelial dysfunction came from TREND Study [219]. This 
double-blind, randomized, placebo-controlled trial strongly sup-
ported the hypothesis that ACE inhibition (obtained here using 
quinapril), improves endothelial dysfunction of the coronary arter-
ies. Only quinapril induced net change in the acetylcholine-
provoked constriction of target segments of the coronaries after 6 
months of treatment in a population formed of normotensive pa-
tients with coronary artery disease and without confounding vari-
ables such as heart failure, cardiomyopathy, or major lipid abnor-
malities. Similar results of improvement of flow-dependent endo-
thelium-mediated vasodilation are reported in further two studies: 
the first, even in subjects affected by CAD, reported a similar extent 
of reduction after 4 weeks of therapy with ramipril 10 mg/d or 
losartan 100 mg/d through increase of bioavailability of NO [220]; 
the second, evaluated in renal circulation, after once daily treatment 
with 40/80 mg telmisartan or 5/10 mg ramipril for 9 weeks [221]. 
No significant differences between the two drugs were observed 
although the ARB seemed to be a little more efficient. 
 Given what showed in the TREND trial [219] about the effec-
tiveness of quinapril in improve endothelium function, in BANFF 
Study [222] were compared the same quinapril 20 mg with enala-
pril 10 mg, losartan 50 mg or amlodipine 5 mg daily. The study 
enrolled 80 patients with CAD randomly assigned to one of the 
selected treatments. The change in FMD from baseline was signifi-
cant only for quinapril (1.8 +/- 1%, p < 0.02). No change was seen 
with losartan (0.8 +/- 1.1%, p = 0.57), amlodipine (0.3 +/- 0.9%, p 
= 0.97) or enalapril (-0.2 +/- 0.8%, p = 0.84). This finding appears 
very interesting because shows that if different ARBs exert their 
function though an unique mechanism (blocking of AT1 receptor) 
different ACEis, acting in various extent against plasmatic ACE 
and tissue ACE might provide different ancillary effects. In BANFF 
study, for example, the ACEi that resulted not able to affect endo-
thelial function, enalapril, is an ACEi with low activity at the tissue 
level. 
 Regarding effect of ACE-i on circulating adhesion molecules 
levels, in 1998 Ferri et al [223] evaluated circulating soluble E-
selectin, ICAM-1, and VCAM-1 concentrations in 93 nonobese 
essential hypertensive patients hyperilipidemic and/or with im-
paired glucose tolerance, matching data with those collected in a 
group of 22 healthy volunteers served as a control group. Soluble 
adhesion molecules were measured at baseline, during an oral glu-
cose tolerance test, and after 12 weeks of either enalapril or placebo 
treatments. Authors reported that, compared with placebo, 12 weeks 
of enalapril treatment significantly (P < 0.0001) reduced soluble E-
selectin, ICAM-1, and VCAM-1 (60-70% decrease in all circulating 
adhesion molecules tested). Decrements of soluble adhesins were 
not dependent on enalapril-related blood pressure changes.  
 Analysing data provided by Gasic et al, [224] the ACEi fosino-
pril (10 mg/day) administered over 12 weeks to 11 microalbuminu-
ric patients with non-insulin-dependent diabetes mellitus (NIDDM) 
provided the following actions: serum levels of cVCAM-1 de-
creased by -19% (CI: -25% to -13%) after treatment with fosinopril 
(P = .003) and were no longer different from those of the control 
group. In contrast, plasma levels of E-selectin, ICAM-1, plasmino-
gen activator inhibitor (PAI-1) and tissue plasminogen activator 
(TPA) were unaffected. In the population enrolled baseline levels of 
baseline plasma concentrations of E-selectin, ICAM-1, and VCAM-
1 were markedly higher in patients than in healthy control subjects 
(n = 82; P < .001), mechanisms behind diabetic endothelial dys-
function and, as a consequence, ancillary effects of ACE-inhibition 
in diabetic population not necessarily might be similar to healthy 
subjects. Nevertheless of this fosinopril in this trial did not reach 
the lowering of both the adhesion molecules and the fibrinolitic 
markers tested.  
 The effects of blockade of the RAAS on levels of circulating 
adhesion molecules in type 1 diabetic patients with diabetic neph-
ropathy were assessed by Andersen et al [225]. The study was de-
signed as a crossover trial with 5 treatment periods, each lasting 2 
months; sixteen patients were included. The patients received the 
AT1 receptor antagonist losartan (50 and 100 mg), the ACE inhibi-
tor enalapril (10 and 20 mg), and placebo in random order. Labora 
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Table 3. Selected Studies Evaluating Anti-inflammatory Effects of Angiotensin Converting Enzyme inhibitors 
Drug Study Main Results 
Enalapril (vs losartan) Guba M et al (2000) [218] Using a hamster dorsal skinfold model, Enalapril significantly reduced early cellular damage, mi-
crovascular perfusion failure, and leukocyte adherence in response to ischemia-reperfusion. Con-
versely, losartan proved to be ineffective at attenuating postischemic microcirculatory disorder. In 
vitro, enalapril reduced PMN adherence and ICAM-1 and VCAM-1 expression, while losartan was 
ineffective. 
Enalapril (vs placebo) Ferri C et al (1998) [223] Compared with placebo, 12 weeks of enalapril treatment significantly (P < 0.0001) reduced soluble 
E-selectin, ICAM-1, and VCAM-1 in hypertensives several of whom had dyslipidemia and/or IGT. 
Fosinopril Gasic S et al (1999) [224] In microalbuminuric patients with NIDDM serum levels of cVCAM-1 decreased by -19%. Plasma 
levels of cE-selectin, cICAM-1, PAI-1 and TPA were unaffected. 
Enalapril (vs losartan) Andersen S et al (2000) 
[225] 
In type 1 diabetic patients with diabetic nephropathy losartan and enalapril reduced similarly 
sVCAM-1 and sEselectin. Losartan provided an higher reduction of sVCAM-1 and sE-selectin (P < 
0.09). The concentration of sICAM-1 remained unchanged. None of the drugs lowered the baseline  
elevated level of vWF or the concentration of CRP. 
Enalapril (vs losartan) Jilma B et al (2002) [226] In 32 previously untreated hypertensives enalapril decreased plasma levels of cE-selectin, cICAM-
1, cVCAM-1 and MCP-1 after 8 weeks of treatment. Losartan did not significantly change cAM or 
MCP-1 plasma concentrations after 8 weeks of treatment: cE-selectin levels decreased by 3%, cI-
CAM-1 by 5%, cVCAM-1 by 8%, whereas MCP-1 increased by 2% (all P=NS) 
Enalapril vs Zofeno-
pril 
Cominacini L et al (2002) 
[227] 
In human umbilical vein endothelial cells zofenoprilat (a sulfhydryl (SH)-containing ACE inhibitor) 
but not enalaprilat reduced ROS formation, VCAM-1, ICAM-1), and E-selectin induced by ox-LDL 
and TNF-alpha. 
Lisinopril (vs Oma-
patrilat) 
Sheth H et al (2002) [228] In 107 HF subjects randomized to either the VPI omapatrilat 40 mg/day or the ACE inhibitor lisi-
nopril 20 mg/day, levels of IL-6 decreased and IL-10 increased in both groups. 
ACE-is (unspecified) Brull DJ et al (2002) [229] In 161 patients undergoing elective first time CABG, after the procedure IL-6 levels were lower in 
ACE-i treated patients than in controls. 
Drug Study Main results 
ACE-is (unspecified) Di Napoli et al (2003) [233] 507 patients with first-ever ischemic stroke. ACEi treatment was associated with lower (2.6-fold; 
P<0.0001) median CRP levels and with a reduced 2-year cardiovascular risk (hazard ratio, 0.39; 
95% CI, 0.29 to 0.53; P<0.0001) compared with a different BP-lowering regimen. 
Enalapril (vs losartan 
and placebo) 
Trevelyan J et al (2004) 
[230] 
In patients underwent to CABG enalapril and losartan reduced similarly IL-6 and IL-1ra levels but 
do not affected IL-10. 
Trandolapril (vs pla-
cebo) 
PEACE trial (2004) [236] In subjects with stable CAD adding on top of previous treatiment of trandolapril 4mg per day  did 
not reduce CRP levels. 
Enalapril (vs irbesar-
tan) 
Schieffer et al (2004) [234] In patients with CAD and arterial hypertension six to eight weeks after coronary angioplasty, after 3 
months of treatment, both enalapril and irbesartan enhanced serum IL-10 levels and reduced serum 
MMP-9 protein and MMP-9 activity. Only IRB reduced serum IL-6 and hsCRP levels significantly 
compared with baseline (p < 0.01), whereas ENAL did not. Platelet aggregation was only reduced 
by IRB while urine PGE(2) levels remained unchanged. 
Quinapril vs enalapril Tsikouris JPet al (2004) 
[237] 
In patients following an acute MI, after 14 days of follow-up quinapril reduced CRP levels to a 
lesser extent than enalapril. 
Ramipril Mitrovic et al (2005) [232] In 24 subjects with documented atherosclerosis after 10 mg/day of ramipril for 3 months CRP levels 
decreased from 3.99±1.61 mg/L to 2.72±1.19 mg/L (–32%). 
Enalapril  (Vs 
candesartan) 
CENTRO trial (2005) [167] In DM type 2 patients Candesartan and enalapril equally reduced circulating level of ICAM-1 and 
exerted comparable effects on changes of other adhesion molecules and coagulation factors. 
Enalapril  (Vs  nifedi-
pine GITS) 
Agabiti Rosei et al (2005) 
[214] 
In hypertensives, 12 weeks of therapy of both enalapril and nifedipine tended to similarly reduce 
ICAM-1 and E-selectin, while only nifedipine reduced von Willebrand factor 
Ramipril  (vs placebo) Koh et al (2005) [239] In hypercholesterolemic patients with type 2 diabetes ramipril (in combination with simvastatin) re-
duced significantly CRP and increased adiponectin. 
 
Effects of ACE-inhibitors and Angiotensin Receptor Current Pharmaceutical Design, 2012, Vol. 18, No. 28    4399 
(Table 3) Contd.... 
 
Drug Study Main results 
Quinapril (vs placebo) Tikiz et al (2005) [235] In rheumatoid arthritis patients quinapril (10 mg/day) added to antirheumatic drugs do not modified 
CRP, fibrinogen, IL-1, IL-6 and TNF- levels. 
Drug Study Main results 
Quinapril vs enalapril Kovacs I et al (2006) [231] In post-MI patients FMD (marker of endothelial dysfunction), increases after 8 weeks of treatment 
with quinapril but not enalapril. TNF-alpha (19.0+/-12.21 pg/ml) and CRP (to 3.91+/-1.82 mg/L) 
significantly decreased after 8 and 12 weeks of quinapril treatment but not after enalapril treatment. 
Ramipril  (vs placebo) Brili S et al (2008) [240] In normotensive subjects with successfully repaired coarctation of the aorta (SCR) ramipril 5 
mg/day for 4 weeks improved endothelial function (p < 0.001) and decreased the expression of the 
cytokine IL-6 (p < 0.05), sCD40L (p < 0.01) and sVCAM-1 (p < 0.01), but failed to affect serum 
levels of C-reactive protein. 
Perindopril (vs irbe-
sartan and placebo) 
Tousoulis D et al (2008) 
[241] 
In 60 normotensive patients with CAD, both perindopril and irbesartan similarly reduced fibrinogen 
and hsCRP without changing levels of sICAM-1, sVCAM-1, E-selectin and TNF-. 
Perindopril vs Enala-
pril (vs placebo) 
Krysiak et al (2008) [242] In normotensive patients with stable CAD Perindopril significantly reduced plasma levels of oxi-
dized LDLs, CRP, MCP-1, fibrinogen and PAI-1, and increased interleukin-10. The effect of enala-
pril on these markers was much less pronounced. 
Fosinopril (vs pla-
cebo) 
TRAIN Study (2009) [243] Subjects 55 years old with high cardiovascular disease risk profile. Fosinopril did not modify 
CRP, IL-6, PAI-1, VCAM-1, endothelin 1. 
Ramipril  (vs placebo) 4R Trial (2009) [238] 264 subjects with CRP levels > 2 mg/dl. 10 mg/day of ramipril for 12 weeks did not lower CRP 
levels compared with placebo 
PMN: polymorphonuclear; ICAM-1: intercellular adhesion molecule-1; VCAM-1: vascular adhesion molecule-1; IGT: Impaired Glucose Tolerance; NIDDM: non-insulin-dependent 
diabetes mellitus; PAI-1: plasminogen activator inhibitor; TPA: tissue plasminogen activator; vWF. Von Willebrand Factor; TNF-alpha: Tumor Necrosis Factor-alpha; CRP: C Reac-
tive Protein; MCP-1: monocyte chemoattractant protein-1; NS: not significant; ROS: Reactive Oxygen Species; CAD: coronary artery disease; HF: Heart Failure; VPI: Vasopeptidase 
Inhibitor; CABG: coronary artery bypass graft; IL-1ra: IL-1 receptor antagonist; MMP: Matrix metalloproteinase; DM: diabetes mellitus; FMD: Flow Mediated Dilatation. 
 
tory examinations were performed at the end of each treatment 
period and included assessment of plasma sVCAM-1; sICAM-1; 
sE-selectin. Von Willebrand factor (vWF), and CRP. These mark-
ers, except sICAM-1, were also examined in a control group of 29 
healthy subjects. Plasma levels of sVCAM-1, sE-selectin, and vWF 
during the placebo period were higher than those in healthy control 
subjects. The increased concentrations of sVCAM-1 and sEselectin 
in the patients with diabetic nephropathy were significantly reduced 
by blockade of RAS, both by losartan and enalapril, except for sE-
selectin in the losartan-treated patients (P = 0.08). The relative re-
ductions in sVCAM-1 and sE-selectin obtained during treatment 
with the AT1 receptor antagonist tended to be less pronounced than 
the reduction obtained with the ACE inhibitor (P < 0.09). The con-
centration of sICAM-1 remained unchanged in all 5 treatment peri-
ods. None of the drugs lowered the elevated level of vWF or the 
concentration of CRP. This study seems likely to demonstrate that 
blockade of the activity of angiotensin II in diabetic nephropathy 
lowers the levels of some, but not all, adhesion molecules 
(sVCAM-1 and cE-selectin only, reduced levels by approx. 10%). 
These results suggest that interfering with the effects of angiotensin 
II decreases proatherogenic endothelial-leukocyte adhesion in dia-
betic nephropathy, without acting on all the pro-inflammatory 
mechanisms. Levels of vWF and CRP did not change, which sug-
gests that a general improvement in endothelial function or a de-
crease in systemic inflammatory activity did not cause the decreases 
in sVCAM-1 and sE-selectin. 
 Jilma et al tested the hypothesis whether enalapril effectively 
decrease plasma levels of circulating adhesion molecules (cAMs) as 
showed by the previous reports [226]. To examine whether this 
effect may be mediated by the decreased action of angiotensin, 
authors compared the effects of enalapril with the ARB, losartan, 
on plasma levels of cAMs, and monocyte chemotactic protein-1 
(MCP-1). In a randomized trial, they recruited 32 untreated patients 
(19 male, aged 59+/-13 years) with hypertension, who received 
either enalapril (mean dose 17 mg/day) or losartan (mean dose 77 
mg/day) at equipotent doses. Enalapril decreased plasma levels of 
all cAMs after 8 weeks of treatment: cE-selectin levels decreased 
by 13% (P=0.007), cICAM-1 by 15% (P=0.002) and cVCAM-1 by 
19% (P=0.003). Similarly, enalapril decreased plasma levels of 
MCP-1 by 13% (P<0.001). Losartan did not significantly change 
cAM or MCP-1 plasma concentrations after 8 weeks of treatment: 
cE-selectin levels decreased by 3%, cICAM-1 by 5%, cVCAM-1 by 
8%, whereas MCP-1 increased by 2% (all P=NS; not significant). 
The enalapril effect on percentage changes of cVCAM-1 was sig-
nificantly different from losartan (P=0.0429). So, eight weeks of 
antihypertensive treatment with enalapril but not losartan, signifi-
cantly decreased plasma levels of cAMs and MCP-1 in hyperten-
sive patients. The somewhat surprising difference between treat-
ment with an ACE-i and an ARB in this paper suggests that the 
cAM lowering effects of ACE-Is might at least in part due to a 
mechanism other than inhibition of angiotensin generation and 
action. 
 Likewise this, but comparing two ACEis: enalapril and zofeno-
pril [227], authors tested the effectiveness of these two molecules 
on the cellular redox state (monitored by measuring intracellular 
reactive oxygen species and thiol status), expression of adhesion 
molecules, and activation of NF-kB in human umbilical vein endo-
thelial cells (HUVECs). Zofenoprilat, the active form of zofenopril, 
significantly and dose dependently reduced the intracellular ROS 
and superoxide formation induced by oxidized low-density lipopro-
tein (ox-LDL) (P <.001) and TNF-alpha (P <.001). Enalaprilat, the 
active form of enalapril, was ineffective. Zofenoprilat but not 
enalaprilat also decreased the consumption of the intracellular GSH 
induced by ox-LDL (P <.01) and TNF-alpha (P <.01). Although 
zofenoprilat significantly and dose dependently reduced the expres-
sion of VCAM-1, ICAM-1, and E-selectin induced by ox-LDL (P 
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<.01) and TNF-alpha (P <.01) on HUVECs, enalaprilat did not. Ox-
LDL and TNF-alpha increased the activation of NF-kB and the 
preincubation of HUVECs with zofenoprilat, but not with enalapri-
lat, dose dependently reduced its activation (P <.001). The author’s 
conclusion is that the sulfhydryl (SH)-containing ACE inhibitors 
may be useful in inhibiting foam cell formation and thus slow the 
development of atherosclerosis, hypothesizing a differential anti-
inflammatory effect inside ACE-i class. It should be noticed, once 
again, how in trials evaluating effects of ACE-i beyond a clinical 
setting, without testing the drugs in real condition of over-activation 
of RAAS such as in hypertensive patients, results found are signifi-
cantly different, likewise is seen for lack of effectiveness of enala-
pril in this paper. 
 In the IMPRESS Trial [228], 107 heart failure patients, New 
York Heart Association functional class II to III, with left ventricu-
lar ejection fraction <40%, were randomized to either the Vasopep-
tidase inhibitor (VPI) omapatrilat 40 mg/day or the ACEi lisinopril 
20 mg/day. After 24 weeks of follow-up C-terminal atrial natri-
uretic peptide (C-ANP) levels decreased with lisinopril (p = 0.035), 
but not with omapatrilat. In contrast, N-terminal ANP levels did not 
change, and brain natriuretic peptide (BNP) levels tended to de-
crease similarly in both groups. Endothelin-1 levels increased in 
both groups. Levels of the proinflammatory cytokine IL-6 tended to 
decrease, and the anti-inflammatory cytokine IL-10 increased in 
both groups, with statistical significance only for interleukin-10 
with omapatrilat therapy. 
 Evaluation of anti-inflammatory effect of ACE-i after coronary 
artery bypass graft surgery (CABG) was the aim of a study de-
signed by Brull et al [229]. Authors recruited 161 patients undergo-
ing elective first time CABG, of whom 41 (25%) were receiving 
ACE inhibitor treatment. Baseline IL-6 concentrations (geometric 
mean (SEM)) were non-significantly lower among the patients 
receiving ACE inhibitors (3.7 (0.1) v 4.3 (0.1) pg/ml, p = 0.12). 
Overall, post-CABG IL-6 concentrations increased significantly 
(mean rise 177 (12) pg/ml, p < 0.0005). This response was blunted 
among ACE inhibitor treated patients. Median increases in IL-6 
concentrations were 117 v 193 pg/ml, for treated v non-treated pa-
tients, respectively (Kruskal-Wallis, p = 0.02), with peak postopera-
tive IL-6 concentrations lower among the subjects receiving ACE 
inhibitors than in untreated subjects (142 (19) v 196 (13) pg/ml, p = 
0.02). The effect of ACE inhibitors remained significant after mul-
tivariate analysis (p = 0.018). In these data early ACE inhibition 
after CABG treatment was associated with a reduction of IL-6 con-
centration. 
 In another set of data in patients underwent to CABG was col-
lected by Trevelyan et al [230] comparing effects of enalapril, 
losartan, or placebo on systemic IL-6, IL-8, IL-10, and IL-1ra lev-
els. Enalapril and losartan significantly decreased release of the IL-
1ra after CABG. Enalapril produced a highly significant decrease of 
51% in the release of IL-6 in patients identified as high producers 
of IL-6 by the -174 G/C polymorphism, whereas losartan has a 
similar but less marked effect. Release of IL-10 was nonsignifi-
cantly decreased (26% by enalapril and 21% by losartan), whereas 
IL-8 was not detected. 
 Effects of ACEIs, on inflammatory systemic biomarkers such 
as CRP were investigated in a small study by Kovacs et al [231]. 
The authors hypothesized that the magnitude of flow mediated dila-
tation (FMD) of the brachial artery of post myocardial infarction 
patients will correlate with serum levels of TNF-alpha, CRP, and 
that treatment with ACEi will increase FMD by reducing TNF-
alpha and CRP. Patients were treated with low dose (10 mg/day) 
quinapril or enalapril and their effects on FMD and inflammatory 
markers were evaluated after 8 and 12 weeks. In the Quinapril 
group, but not in the Enalapril group FMD increased significantly, 
(to 5.96+1.10%), whereas TNF-alpha (19.0+/-12.21 pg/ml) and 
CRP (to 3.91+/-1.82 mg/L) significantly decreased after 8 and 12 
weeks of quinapril treatment. Moreover, the magnitude of FMD 
showed a strong inverse correlation with serum levels of TNF-alpha 
and CRP after treatment with quinapril. Thus, in post myocardial 
infarction the endothelial dysfunction assessed by FMD correlates 
with elevated levels of plasma inflammatory markers, and low dose 
quinapril improves endothelial function, likely by reducing vascular 
inflammation. 
 Mitrovic et al [232] reported results of an uncontrolled, open-
label study of 10 mg/day of ramipril in 24 subjects with docu-
mented atherosclerosis. CRP levels decreased from 3.99±1.61 mg/L 
to 2.72±1.19 mg/L (-32%) after three months, and this effect was 
greater in patients not treated with statins. 
 Di Napoli and Papa [233] conducted a prospective observa-
tional study of 507 patients with first-ever ischemic stroke to ana-
lyze the effect of ACEi treatment at the time of stroke onset on CRP 
levels within the first 24 h and the relationship to outcome. The 
authors reported that ACEi treatment was associated with lower 
(2.6-fold; P<0.0001) median CRP levels and with a reduced 2-year 
cardiovascular risk (hazard ratio, 0.39; 95% CI, 0.29 to 0.53; 
P<0.0001) compared with a different BP-lowering regimen. The 
relationship between ACE inhibitor status and log-normalized CRP 
levels remained significant (P<0.0001) after control for important 
confounding variables and concomitant treatments. The reduced 
risk was also evident in multivariable analysis when ACE inhibitor 
treatment was controlled for BP, associated risk factors, neuroradi-
ological findings, and concomitant treatments (hazard ratio, 0.43; 
95% CI, 0.30 to 0.62; P<0.0001). This risk reduction was greatly 
attenuated and not more significant when log-normalized CRP lev-
els were included (hazard ratio, 0.67; 95% CI, 0.43 to 1.04; 
P=0.0721) in the model. So, in the specific asset of acute stroke, 
ACE inhibition seems to be associated with lower inflammatory 
response and better long-term outcomes, apparently apart from the 
effects on BP. 
 In a very interesting small randomized study, Schieffer et al 
[234] assessed, comparing effects of ACEis and ARBs, whether 
RAS inhibition elicits anti-inflammatory and antiaggregatory ef-
fects in patients with CAD and arterial hypertension six to eight 
weeks after coronary angioplasty. Patients were randomly assigned 
to either 20 mg enalapril (n=27) or 300 mg irbesartan (n=21) for 
three months. Both treatment regimens enhanced serum IL-10 lev-
els (IRB p < 0.001, ENAL p < 0.03) and reduced serum MMP-9 
protein (IRB p < 0.001, ENAL p < 0.05) and MMP-9 activity (IRB 
p < 0.005, ENAL p < 0.05). Only IRB reduced serum IL-6 and 
hsCRP levels significantly compared with baseline (p < 0.01), 
whereas ENAL did not (hsCRP p < 0.02 IRB vs. ENAL, p < 0.01 
IRB vs. ENAL). Platelet aggregation was only reduced by IRB (p < 
0.001, ENAL p < 0.06, IRB vs. ENAL p < 0.001) while urine PGE 
(2) levels remained unchanged. ACE inhibition and AT1 blockade 
reduced serum MMP-9 protein/activity to a similar extent, and only 
AT1 blockade reduced hsCRP, IL-6, and platelet aggregation in 
patients with CAD. Thus, AT1-blockade appears to exert stronger 
systemic anti-inflammatory and anti-aggregatory effects compared 
with ACE inhibition. This small trial prefigures the concept of the 
likely greater anti-inflammatory effect of ARBs in comparison to 
ACEis that will be better addressed in the latter part of this review. 
 The peculiar asset of rheumatoid arthritis (RA) and the possible 
activities of the ACEis and of the statins (hydroxy-methyl-glutaryl-
CoA reductase inhibitors) on the inflammatory markers and endo-
thelial functions in these patients were investigated by Tizik et al 
[235]. A total of 45 patients with longterm RA were randomized 
into 3 groups to receive 8 weeks of treatment with placebo (n = 15), 
simvastatin (20 mg/day, n = 15), or quinapril (10 mg/day, n = 15) as 
an adjunct to existing antirheumatic drug treatment. CRP, fibrino-
gen, nitric oxide (NO), and serum cytokine concentrations includ-
ing IL-1beta, IL-6, and TNF-alpha were measured at baseline and 
in the post treatment period. Quinapril was found to have no sig-
nificant effects on inflammatory markers and endothelial vasodila-
tor response. Analysing this interesting report we could speculate 
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how inflammation per se do not represent the target of ACE inhibi-
tion, that only in presence of RAAS hyperactivation exerts an anti-
inflammatory effect.  
 In the CENTRO trial [167], a comparative, multicenter, ran-
domized and double blind, with two parallel groups study, in the 
same way authors compared the effects of an ACEi, enalapril and 
an highly selective ARB, candesartan cilexetil, on circulating adhe-
sion molecules in a large sample of patients with non-insulin-
dependent diabetes mellitus (NIDDM), enalapril and Candesartan 
showed similar effects on blood pressure and on circulating adhe-
sion molecules. Candesartan and enalapril equally reduced circulat-
ing level of ICAM-1 and exerted comparable effects on changes of 
other adhesion molecules and coagulation factors. A similar blood 
pressure-lowering effect was observed with the two drugs (cande-
sartan: from 148/90 +/- 11/8 to 132/82 +/- 12/7 mmHg, P < 0.01, 
enalapril: from 148/91 +/- 12/8 to 131/85 +/- 14/6 mmHg, P < 
0.01). Candesartan was more effective than enalapril in the reduc-
tion of albuminuria (P < 0.05 between treatments), although urinary 
protein excretion can be considered normal in the majority of pa-
tients. So, in this trial, enalapril seem to be equivalent to candesar-
tan, being both effective in reducing circulating adhesion molecules 
levels in diabetic population. 
 Even this italian group designed a study aimed to compare the 
effects of nifedipine GITS 20 mg (Nifedipine gastrointestinal thera-
peutic system (GITS) 20 mg is a new low-dose formulation with an 
improved tolerability) and enalapril 20 mg on blood pressure and 
circulating adhesion molecules in a randomized, double-blind, mul-
ticentre trial during 12-week in patients with mild-to-moderate 
hypertension [214]. Nifedipine GITS 20 mg induced a reduction of 
clinic blood pressure, which was similar to that observed with 
enalapril 20 mg. Nifedipine GITS and enalapril lowered mean sit-
ting diastolic blood pressure by 11.8 and 12.4 mmHg, respectively, 
while systolic blood pressure was reduced by 15.3 and 16.3 mmHg, 
respectively. Ambulatory blood pressure monitoring-derived blood 
pressure data showed similar results in both groups without any 
statistically significant differences between treatments. Both enala-
pril and nifedipine tended to reduce ICAM-1 and E-selectin, while 
only nifedipine reduced von Willebrand factor. Both treatments 
were well tolerated. This trial demonstrated how also other anti-
hypertensive drugs might exert anti-inflammatory effects and, 
probably, as reported previously, BP reduction per se may lead to a 
reduction of systemic inflammation. 
 CRP levels after ACEi therapy was also measured in the Pre-
vention of Events with Angiotensin-Converting Enzyme Inhibition 
(PEACE) trial [236], in subjects with stable CAD. The trial was a 
double-blind, placebo-controlled study in which 8290 patients were 
randomly assigned to receive either trandolapril at a target dose of 4 
mg per day (4158 patients) or matching placebo (4132 patients). 
While CRP was predictive of events, treatment with trandolapril 
4mg per day did not reduce CRP levels. Further, in this trial, in 
patients with stable coronary heart disease and preserved left ven-
tricular function who are receiving "current standard" therapy and 
in whom the rate of cardiovascular events is lower than in previous 
trials of ACE inhibitors in patients with vascular disease, no evi-
dence that the addition of an ACE inhibitor provides further benefit 
in terms of death from cardiovascular causes, myocardial infarction, 
or coronary revascularization. 
 Because vascular inflammation contributes to adverse outcomes 
following acute myocardial infarction (AMI), Tsikouris et al hy-
pothesized that high-tissue penetrating ACE inhibitors (quinapril) 
would provide more favourable effects on CRP after AMI com-
pared to low-tissue penetrating ACE inhibitors (enalapril) [237]. 
After 14 days of follow-up quinapril reduced CRP levels to a lesser 
extent than enalapril.  
 In 2009, a similar study, the 4R Trial [238], a 12-week random-
ized, double-blind, placebo-controlled study, enrolled a total of 264 
men and women, with CRP levels of 2 mg/L or greater and no his-
tory of cardiovascular disease. Patients were randomly assigned to 
receive 10 mg/day of ramipril (n=132) or placebo (n=132) for 12 
weeks in order to assess CRP differences between the two groups. 
The percentage change in geometric mean CRP values over 12 
weeks was -13.2% in the placebo group compared with -21.1% in 
the ramipril group (P nonsignificant), indicating no significant re-
duction in the primary end point of the trial. Ramipril did not lower 
CRP levels compared with placebo; probably a larger sample and a 
longer duration of intervention were necessary to evaluate a pa-
rameter such as CRP, as concluded by the authors. The data ob-
tained through these two trials show how the reduction of CRP 
serum levels as a consequence of ACE inhibition appears no to be 
as immediate as we can expect. CRP, otherwise from other inflam-
matory markers is linked and regulated by various factor, and a 
single intervention correcting one of these, as ACE inhibition is, 
probably do not reach a significant clinical effect. Obviously, other 
larger trials are needed to clarify this topic. 
 The link between ACEi and statin concurrent therapy was 
tested by Koh in 2005 [239], assuming that because the impact of 
simvastatin and ramipril therapies on NO bioactivity, oxidant stress, 
inflammation, endothelial function, and insulin resistance may dif-
fer, the combined therapy may have additive beneficial effects that 
are greater than those observed with either simvastatin or ramipril 
therapy alone in hypercholesterolemic patients with type 2 diabetes. 
This was a randomized, double-blind, placebo-controlled crossover 
trial with 3 treatment arms (each 2 months) and 2 washout periods 
(each 2 months). Fifty patients with type 2 diabetes were given 
simvastatin 20 mg and placebo, simvastatin 20 mg and ramipril 10 
mg, or ramipril 10 mg and placebo daily during each 2-month 
treatment period. Ramipril alone or combined therapy significantly 
reduced blood pressure when compared with simvastatin alone. 
When compared with ramipril alone, simvastatin alone or combined 
therapy significantly improved the lipoprotein profile. All 3 treat-
ment arms significantly improved flow-mediated dilator response to 
hyperemia and reduced plasma levels of malondialdehyde relative 
to baseline measurements. However, these parameters were 
changed to a greater extent with combined therapy when compared 
with simvastatin or ramipril alone (P<0.001 by ANOVA). When 
compared with simvastatin or ramipril alone, combined therapy 
significantly reduced high-sensitivity CRP levels (P=0.004 by 
ANOVA). Interestingly, combined therapy or ramipril alone sig-
nificantly increased plasma adiponectin levels and insulin sensitiv-
ity relative to baseline measurements. These changes were signifi-
cantly greater than in the group treated with simvastatin alone 
(P<0.015 by ANOVA). Ramipril combined with simvastatin had 
beneficial vascular and metabolic effects when compared with 
monotherapy in patients with type 2 diabetes. Interestingly, fur-
thermore of addressing the issue of the greater efficacy of the asso-
ciation ACEi plus statin this work, for the first time demonstrates 
that ramipril therapy might increase adiponectin levels, improving 
both insulin sensitivity and endothelial function by multiple mecha-
nisms. 
 The effect of the ACEi ramipril on endothelial function and 
inflammatory process was studied in a group of normotensive sub-
jects with successfully repaired coarctation of the aorta (SCR) in a 
work by Brili et al [240], Twenty young individuals age 27.3 +/- 
2.4 years old with SCR 13.9 +/- 2.2 years previously, received 
ramipril 5 mg/day for 4 weeks in a randomized, cross-over, con-
trolled trial. Endothelial function was evaluated in the right forearm 
by gauge-strain plethysmography, and serum levels of IL-1, IL-6, 
soluble CD40 ligand (sCD40L), and soluble VCAM-1 were deter-
mined by enzyme-linked immunosorbent assay. Ramipril improved 
endothelial function (p < 0.001) and decreased the expression of 
proinflammatory cytokine IL-6 (p < 0.05) and sCD40L (p < 0.01). 
Furthermore, ramipril decreased serum levels of sVCAM-1 (p < 
0.01) but, once again, failed to affect serum levels of CRP. These 
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effects were independent of blood pressure lowering. These find-
ings would imply that ramipril treatment may have antiatherogenic 
effects also in a so peculiar class of subjects such as patients with 
SCR, even in the absence of arterial hypertension. 
 The same group, in 2008 [241], compared the effect of the 
ACEi perindopril with the AT1 blocker irbesartan on endothelial 
function and the expression of inflammatory markers TNF-, solu-
ble VCAM-1, soluble ICAM-1, E-selectin, hsCRP and fibrinogen, 
in normotensive patients with CAD. Sixty normotensive patients 
with stable CAD were randomly allocated into 3 groups, to receive 
irbesartan (75 mg/day), perindopril (2 mg/day) or no antihyperten-
sive agent (control group) for 4 weeks. Both irbesartan and perin-
dopril decreased systolic and diastolic blood pressure, having no 
effect on pulse pressure and improved maximum hyperemic fore-
arm blood flow. Both fibrinogen and hsCRP were decreased in 
irbesartan and perindopril-treated groups, while there was no 
change in the control group. There was no significant difference of 
the change in fibrinogen or hsCRP between irbesartan and perindo-
pril-treated groups. There was no significant change in serum levels 
of sICAM-1, sVCAM-1, E-selectin and TNF- in any of the 3 study 
groups after treatment. The authors conclude that although low dose 
irbesartan and perindopril have similar effects on acute phase pro-
teins in normotensive patients with CAD, they fail to affect other 
inflammatory markers with critical role in atherogenesis. This could 
be a result of the short treatment period or the consequence of the 
low dose of the two drugs used in this study, although a differential 
response of normotensive patients with CAD to these drugs cannot 
be excluded. These results further confirm the fact that the analysis 
of available evidences shows an heterogeneity of effects of ACEi 
on inflammatory markers; this definite variability of effects may be 
probably related to experimental conditions, dosage of drugs, dura-
tion of treatment and characteristic and timing of markers dosage. 
 The ancillary anti-inflammatory properties of perindopril (4 
mg/day) and enalapril (20 mg/day) vs placebo in normotensive 
patients with stable CAD was the aim of another study [242]. 
Plasma lipid profile and the levels of oxidized low density lipopro-
teins (LDLs), MCP-1, IL-10, CRP, fibrinogen and PAI-1 were de-
termined at the beginning of the study and after 30 and 90 days of 
treatment. Perindopril significantly reduced plasma levels of oxi-
dized LDLs, CRP, MCP-1, fibrinogen and PAI-1, and increased 
interleukin-10. The effect of enalapril on these markers of systemic 
inflammation, hemostasis and oxidative functions was much less 
pronounced. 
 In one of the latest trial about anti-inflammatory effects of ACE 
inhibition, has been tested ACE inhibition with fosinopril analyzing 
data from the Trial of Angiotensin Converting Enzyme Inhibition 
and Novel Cardiovascular Risk Factors (TRAIN) study, [243] a 
double-blind, crossover, randomized, placebo-controlled trial en-
rolling subjects 55 years old with high cardiovascular disease risk 
profile. Biomarkers of hemostasis (ie, PAI 1, D-dimer), inflamma-
tion (ie, CRP, IL-6), and endothelial function (ie, endothelin 1, 
VCAM 1) were measured at the baseline, at the midterm, and at end 
of follow-up (after 1 year) clinic visits. No significant differences 
were reported for CRP, IL-6, PAI-1, VCAM-1, and endothelin 1 
levels in the comparisons between fosinopril and placebo interven-
tions. D-dimer was the only biomarker showing a significant differ-
ence between fosinopril intervention (median 0.32 μg/mL, inter-
quartile range 0.22-0.52 μg/mL) and placebo (median 0.29 μg/mL, 
interquartile range 0.20-0.47 μg/mL, P = .007). From analysis of 
their data authors concluded that ACE inhibition does not signifi-
cantly modify major biomarkers of inflammation, hemostasis, and 
endothelial function, although further studies should have con-
firmed the possible effect of ACE inhibitors on the fibrinolysis 
pathway [234]. These really discouraging findings might be specifi-
cally related to the ACE inhibitor molecule adopted in the TRAIN 
study (ie, fosinopril). It should not be excluded that different results 
might be found with the use of other ACEis although there is an 
overall agreement suggesting the efficacy of individual ACE inhibi-
tors to be equivalent. 
 In conclusion, actually there is no convincing evidence indicat-
ing that ACE inhibitors reduce plasma levels of major inflammatory 
markers in hypertension models. Lack of evidence concerns espe-
cially those inflammation markers, such as fibrinogen of CRP, 
which are less closely related to atherosclerotic disease and vascular 
damage and conversely are more aspecific . 
 Results of the trials showed previously are often heterogeneous 
and not univocal. Reasons for these discrepancies are unclear but 
may be related to type and/or dose of medication used, characteris-
tics of population enrolled (different in almost any trial), comorbil-
ity, severity of hypertension or diabetes or CAD, entity of cardio-
vascular risk, baseline inflammatory state, and presence of other 
confounding pro-inflammatory conditions. 
 Trying to understand this lack of certain effectiveness of ACE-
inhibition on inflammation mechanisms, the main element sug-
gested is the target of the effects of these drugs: against ACE and 
not directly affecting the Ang II activity, which is more strictly 
implicated in the increased inflammatory status in hypertensives 
and in all the conditions associated to increased Ang II levels. Fur-
ther investigations are required to evaluate whether ACE inhibition 
exerts significant anti-inflammatory effects both in hypertensive 
patients and in other clinical model of cardiovascular and metabolic 
diseases. 
PART V - ANTI-INFLAMMATORY EFFECTS OF ARBS 
 Similarly to what happened for ACEis, animal studies using 
ARBs showed a significant reduction of BP levels and of the pro-
gression of atherosclerotic damage. In studies in hypercholes-
terolemic monkeys, losartan and olmesartan reduced fatty streak 
formation in the aorta, with a corresponding decrease in the levels 
of the inflammatory biomarkers. [244,245]. It is important to note 
that no differences of blood pressure values were noted between 
controls and drug-treated animals in either of these studies, suggest-
ing that the anti-inflammatory and antiatherogenic actions of these 
two ARBs were independent of their effects on blood pressure. 
Differently from ACE inhibitors, the protective effect of ARBs was 
observed at both high and low doses suggesting a possible dose-
dependent effect not confirmed afterwards. 
 Support for the anti-inflammatory effects of ARBs is provided 
by in vitro data showing that the exposure of human monocytes to 
irbesartan or losartan dose dependently inhibited the production of 
MCP-1, as well as low-density lipoprotein cholesterol and plasma 
activating factor-stimulated MCP-1 expression. [246].  
 Anti-inflammatory effects exerted by the ARB valsartan in 
mononuclear cells of normal subjects are reported by Dandona et al 
in 2003 [247]. In view of the pro-oxidant and proinflammatory 
effects of ang II, authors have tested the hypothesis that the ARB 
valsartan, may exert a suppressive action on ROS generation, NF-
B in mononuclear cells. Four groups of eight normal subjects were 
given 1) 160 mg daily of valsartan, 2) 80 mg daily of simvastatin, 
3) 40 mg quinapril, or 4) no treatment. Fasting blood samples were 
obtained before treatment and at d 1, 8, and 14 (7 d after the cessa-
tion of the drug). After valsartan, ROS generation by polymor-
phonuclear cells and mononuclear cells fell significantly by more 
than 40% (P < 0.01). NF-B binding activity and the expression of 
total cellular p65, a protein component of NF-B, fell significantly 
(P < 0.01). The expression of inhibitor B (I-B) increased signifi-
cantly (P < 0.05). Plasma CRP concentration fell significantly (P < 
0.01). All indices, except I B, reverted toward baseline, 7 d after 
the cessation of the drug. I-B persisted in an elevated state. Neither 
quinapril nor simvastatin given for seven days produced a suppres-
sion of ROS generation, intranuclear NF-B, p65, or CRP, and 
these two agents did not alter cellular I-B either. The untreated 
controls also did not demonstrate a change in their ROS generation 
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or NF-B binding activity or plasma CRP concentration. The con-
clusions were that valsartan at a modest dose exerts a profound and 
rapid ROS and inflammation-suppressive effect that may be rele-
vant to its potential beneficial effects in atherosclerosis, diabetes, 
and congestive cardiac failure. In contrast, quinapril and simvas-
tatin produced no similar effect over the period of one week. These 
observations may also extend the effects of valsartan to all the 
clinical situations in which a rapid ant-inflammatory effect is re-
quired.  
 The relationship about the taking of different class of anti-
hypertensive drugs and serum CRP levels was investigated by Pal-
mas et al among participants with treated hypertension in the Multi-
Ethnic Study of Atherosclerosis [248] (see Table 4). The study was 
a cross-sectional study of hypertensive participants free of clinical 
cardiovascular disease who were taking one or more of the follow-
ing medication classes: beta-blockers, calcium channel blockers, 
diuretics, and ACEi or ARBs. Among 2340 participants taking one 
or more antihypertensive medications, the mean serum CRP level 
was lower among participants taking a beta-blocker than among 
those not taking a beta-blocker (2.13 v 2.54 mg/L, P = .002). This 
difference persisted after multivariate adjustment (P = .021). 
Among 1314 participants receiving monotherapy, the multivariate 
adjusted mean CRP level among participants taking a beta-blocker 
was lower (1.97 mg/L) than those taking a diuretic (2.72 mg/L, P < 
.001). In this monotherapy group, participants taking an ACE in-
hibitor or ARB also had a lower adjusted mean CRP (2.25 mg/L) 
than those taking a diuretic (P = .046). African-American 
race/ethnicity did not modify any of those relationships. In conclu-
sion the use of beta-blocker was associated with lower CRP levels 
overall and among participants on monotherapy, whereas ACE 
inhibitor and ARB use was associated with lower CRP levels 
among participants on monotherapy. 
 In a small group of hypertensive patients resistance arteries 
obtained from subcutaneous biopsies were studied before and after 
one year of treatment with either the ARB losartan and the -
blocker atenolol and compared to those of normotensive controls 
[249]. Despite similar reduction in BP, losartan normalized endo-
thelium-dependent relaxation (acetylcholine-induced) and reduced 
media/lumen ratio whereas atenolol had no effect. 
 Effectiveness of losartan in reducing circulating levels of adhe-
sion molecules and ameliorating endothelial dysfunction in eighteen 
healthy older subjects was tested in a study published in 2002 
[250]. Patients were prospectively randomized in a double-blind, 
crossover fashion to receive either losartan 50 mg/day or placebo 
for 6 weeks. Subjects were switched to the opposite arm after a 2- 
week washout period. Flow-mediated dilation (FMD) in the bra-
chial artery and plasma levels of VCAM-1 and ICAM-1, MCP-1, 
and E-selectin were measured in both arms at the beginning and end 
of the 6-week period. Losartan resulted in a 6-mm Hg decrease in 
systolic blood pressure (from 130 +/- 12 to 124 +/- 13 mm Hg), 
which was no different from placebo (132 +/- 12 to 127 +/- 13 mm 
Hg). FMD increased from 3.1 +/- 0.6% to 3.9 +/- 0.6% after losar-
tan, and decreased from 3.3 +/- 0.3% to 2.4 +/- 0.6% after placebo 
(p = NS for both). In contrast, losartan reduced circulating concen-
trations of VCAM-1 (750 +/- 73 to 572 +/- 39), ICAM-1 (405 +/- 
26 to 196 +/- 10), and MCP-1 (560 +/- 56 to 423 +/- 35) (p <0.01 
for all by analysis of variance), but not E-selectin. Thus, vascular 
benefit of administration of losartan for a duration of 6 weeks was 
not univocal in healthy older subjects, infact the ARB has favour-
able effects on inflammatory markers, but does not alter peripheral 
conduit endothelial function. 
 Another similar study regarding the ARB losartan has been 
developed by Sardo et al, in 2004 [251]. The study was designed to 
determine whether the levels of sICAM-1 and TNF-alpha were 
elevated in subjects with uncomplicated hypertension without other 
risk factors or evidence of athero-sclerosis. Twenty hypertensive 
subjects without other risk factors or cardiovascular disease re-
ceived placebo for 4 weeks, then were treated with losartan (50 
mg/day) for 24 weeks. After 4, 12, and 24 weeks of losartan treat-
ment, sICAM-1 and TNF-alpha levels were measured. The same 
parameters were measured in 20 normotensive control subjects (C), 
matched for sex and age. HT had sICAM-1 and TNF-alpha basal 
values higher than C (respectively 351.7 +/-97.4 vs 201.6 +/-32.3 
ng/mL, p<0.001 and 31.8 +/-2.4 vs 15.3 +/-2.2 pg/mL, p<0.001). 
Losartan treatment caused a significant decrease of sICAM-1 levels 
at the end of the first month of treatment (300.2 +/-64.4 ng/mL, 
p<0.05), but the values reverted to the basal levels at the following 
time points. No variation of TNF-alpha levels during losartan 
treatment was observed. These results show that patients with un-
complicated mild essential hypertension presented with high plasma 
ICAM-1 and TNF-alpha concentrations. Although all the patients 
were responsive to the antihypertensive treatment with losartan, 
their plasma concentrations of TNF-alpha were not modified and 
sICAM-1 concentrations decreased only for a short period of time. 
This suggests that in uncomplicated hypertension other factors be-
sides the blood pressure modulate the endothelial inflammation. 
 Another interesting report regarding the ARB losartan regard-
ing the relationship between CRP and AT1 receptors and the phar-
macological modulation of this was published in 2003 [252]. In this 
paper were examinated the effects of losartan on vascular smooth 
muscle (VSM) migration, proliferation, and ROS production CRP-
mediated. From analysis of data collected the authors concluded 
that CRP, at concentrations known to predict cardiovascular events, 
upregulates AT1-R-mediated atherosclerotic events in vascular 
smooth muscle in vitro and in vivo. CRP, furthermore, promoted 
VSM migration and proliferation in vitro and increased ROS pro-
duction. So, CRP would act potentiate the effects of Ang II on these 
processes. In the rat carotid artery angioplasty model, exposure to 
CRP resulted in an increase in cell migration and proliferation, 
collagen and elastin content, and AT1-R expression, as well as an 
increase in neointimal formation; all these effects were attenuated 
by losartan, that would have a marked anti-inflammatory behaviour 
in this area. 
 Trying to address the issue if the ARB irbesartan was able to 
interfere in the atherosclerotic progression trough a supposed anti-
inflammatory effect, Navalkar et al [118] designed a study aimed to 
test effects of irbesartan on specific inflammatory markers included 
solubilized tumor necrosis factor-alpha receptor II (sTNF-aRII), 
VCAM-1 and superoxide in atherosclerotic subjects. With a cross-
sectional study design, 33 normotensive patients with stable CAD 
were treated with irbesartan for a 24-week period. These patients 
were compared against a control population with no known coro-
nary atherosclerosis. serum levels of soluble VCAM-1 were signifi-
cantly increased at interval 0 weeks compared to corresponding 
levels in control patients (466.6 ± 69.7 ng/dl vs. 331.6 ± 39.5 ng/dl 
at 0 weeks). The graph also indicates serum VCAM-1 levels de-
creased significantly in patients with CAD treated with irbesartan as 
compared against control patients over the 24-week study interval 
(325.3 ± 42.3 ng/dl vs. 466.6 ± 69.7 ng/dl at 24 weeks). Patients 
with CAD had an elevated level of TNF-a RII at the zero time in-
terval as compared with their control counterparts (319.15 ± 30.2 
ng/dl vs. 221 ± 63.5 ng/dl). Treatment with irbesartan in the popula-
tion of patients with CAD significantly reduced TNF-aRII levels to 
those of the control population (227 ± 27.9 ng/dl vs. 221 ± 63.5 
ng/dl at 24 weeks). In brief, treatment with irbesartan in these pa-
tients significantly reduced levels of inflammatory molecules meas-
ured. Soluble VCAM-1 levels were reduced by 36%; soluble TNF-
alpha levels were reduced by 54% and superoxide level decreased 
by 52%. Maximal suppression of inflammatory markers by irbesar-
tan therapy in patients with CAD was seen at 12 weeks. 
 Telmisartan, regarding its characteristics, appear to be the most 
peculiar member of the ARB family, infact its ability to partially 
activate the nuclear hormone receptor peroxisome proliferator-
activated receptor gamma (PPAR) at concentrations typically 
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achieved in plasma with conventional oral dosing, would mediate 
several additional metabolic effects beyond BP reduction, such as 
improvement of insulin sensitivity. Chujo et al [253] studied the 
effects of telmisartan treatment on visceral fat, serum adiponectin 
and vascular inflammation markers in Japanese hypertensive pa-
tients. This was an open-label, non-controlled study with a total 
duration of 24 weeks. Twenty-eight essential hypertensive patients 
(22 men and 6 women; age 60.6+/-1.9 years; body mass index 
[BMI] 25.5+/-0.6 kg/m
2
) participated. Fat area was assessed with 
computerized tomography. All the subjects were started on 
telmisartan 40 mg/day, which was increased to 80 mg/day to 
achieve the blood pressure target of less than 130/80 mmHg. There 
were significant reductions in visceral fat area (from 103.1+/-7.9 to 
93.3+/-8.4 cm
2
, p<0.01) and pulse wave velocity (from 1,706+/-52 
to 1,587+/-51 cm/s, p<0.01) at 24 weeks. In contrast, significant 
increases in serum high-density lipoprotein cholesterol (from 
5.06+/-0.15 to 5.32+/-0.13 mmol/L, p<0.05) and adiponectin levels 
(from 8.27+/-0.76 to 9.13+/-0.81 microg/mL, p<0.05) were ob-
served. Also, there were reductions in the interleukin-6 level (from 
2.26+/-0.27 to 1.60+/-0.14 pg/mL, p<0.01). Authors concluded that 
treatment with telmisartan was associated with an improvement of 
vascular inflammation, a reduction of visceral fat and an increase in 
serum adiponectin. 
 An interesting work evaluating ancillary effects of ARBs in 
addiction to rosuvastatin on inflammation and glucose metabolism 
was published recently [254]. In this paper are assumed different 
degrees of efficacy of the three ARBs added to rosuvastatin (olme-
sartan, irbesartan, or telmisartan) on PPAR activity. Infact if 
telmisartan is a partial activator of PPAR, irbesartan is a weak 
partial activator, and olmesartan has no effect on PPAR activation. 
This was a 24-week, randomized, open-label study. After 12 weeks 
of dietary intervention, patients were randomly allocated to receive 
rosuvastatin 10 mg/d plus telmisartan 80 mg/d (RT group), irbesar-
tan 300 mg/d (RI group), or olmesartan 20 mg/d (RO group) for 24 
weeks. The primary end point was change in the following indices 
of glucose metabolism after 6 months of treatment: FPG, homeosta-
sis model assessment of insulin resistance (HOMA-IR), HOMA of 
beta-cell function (HOMA-B), and glycosylated hemoglobin 
(HbA1c). Secondary end points included changes in anthropometric 
variables, blood pressure, serum lipids, and hs-CRP. Tolerability 
was monitored throughout the study. The rosuvastatin-telmisartan 
group showed, in comparison to the other two, favourable effects 
on HOMA-IR, fasting serum insulin, and hs-CRP.  
Table 4. Selected Studies Evaluating Anti-inflammatory Effects of Angiotensin Receptor Blockers 
Drug Study Main results 
Losartan (vs 
atenolol) 
Schiffrin et al 
(2000) [249]  
In hypertensives losartan normalized endothelium-dependent relaxation (acetylcholine-induced) and reduced me-
dia/lumen ratio whereas atenolol had no effect. 
Losartan (vs 
placebo) 
Rajagopalan et 
al (2002) [250]  
In eighteen healthy older subjects, after 6 weeks of treatment losartan increased FMD and reduced circulating levels of 
VCAM-1, ICAM-1 and MCP-1, but not E-selectin. 
Losartan (vs 
placebo) 
Sardo et al 
(2004) [251]  
Twenty hypertensive subjects without other risk factors or cardiovascular disease received losartan (50 mg/day) for 24 
weeks. Losartan caused a significant decrease of sICAM-1 levels without variations of TNF-. 
Irbesartan (vs 
placebo) 
Navalkar et al 
(2001) [118]  
33 normotensive patients with stable CAD were treated with irbesartan for a 24-week period. Irbesartan decreased 
VCAM-1, TNF-aRII and superoxide level.  
Telmisartan  Chujo et al 
(2007) [253]  
In this non-controlled study in hypertensives, 24 weeks of telmisartan treatment (40 up to 80 mg/day) lead to a reduc-
tion in visceral fat area, pulse wave velocity and Il-6 levels whereas HDL cholesterol and adiponectin levels increased. 
olmesartan, 
irbesartan, 
telmisartan 
Rizos et al 
(2010) [254] 
Patients randomly allocated to receive rosuvastatin 10 mg/d plus telmisartan 80 mg/d, irbesartan 300 mg/d, or olme-
sartan 20 mg/d for 24 weeks. The rosuvastatin-telmisartan group showed, in comparision to the other two, favourable 
effects on HOMA-IR, fasting serum insulin, and hs-CRP.  
olmesartan (vs
placebo) 
EUTOPIA trial, 
[207] 
In patients with essential hypertension and assumed vascular microinflammation (ie, hsCRP > 3 mg/L), treatment with 
olmesartan + pravastatin significantly reduced hsCRP, hsTNF-, MCP-1 and IL-6 whereas pravastatin alone did not. 
losartan, irbe-
sartan, cande-
sartan 
Koh et al (2004) 
[256] 
126 hypertensives treated with 50 to 100 mg of losartan, from 150 to 300 mg of irbesartan, and 8 to 16 mg of cande-
sartan over a 2-week period. All the tested ARBs improved FMD without differences. Only candesartan lowered 
MCP-1. Only irbesartan and candesartan lowered PAI-1 antigen levels. None of the affected CRP or TPA. 
Valsartan (vs 
amlodipin) 
Yasunari et al  
(2004) [257] 
Valsartan but not amlodipine reduced CRP levels and formation of ROS by monocytes  
Valsartan  Ridker et al  
(2006) [258] 
1668 stage 2 hypertensives , treated with 160 mg valsartan or 160/12.5 mg valsartan/hydrochlorothiazide (HCTZ) 
once daily for 2 weeks with forced titration to 320 mg valsartan or 320/12.5 mg valsartan/HCTZ for an additional 4 
weeks. Valsartan alone slightly but significantly reduced hsCRP levels, in contrast the combination therapy did not. 
Valsartan  Conen et al 
(2008)  [259] 
In a post-hoc analysis of Val-MARC Trial both valsartan alone and valsartan + HCTZ reduced sICAM-1 and 
sVCAM-1 levels. 
Valsartan (vs 
atenolol) 
Touyz et al 
(2007) [260] 
In patients with hypertension and type 2 diabetes IL-6, IL-18, sICAM, and MCP-1 levels were reduced by valsartan 
(three-fold, P < .05). Only IL-18 was reduced by atenolol compared with pretreatment levels. 
FMD: Flow Mediated Dilatation; ICAM-1: intercellular adhesion molecule-1; VCAM-1: vascular adhesion molecule-1; MCP-1: monocyte chemoattractant protein-1; TNF-: Tumor 
Necrosis Factor-; CAD: coronary artery disease; TNF-aRII; tumor necrosis factor- receptor II; HDL: High Density Lipoprotein; HOMA-IR: homeostasis model assessment of 
insulin resistance; hs-CRP: high-sensitivity C-reactive protein; PAI-1: plasminogen activator inhibitor; TPA: tissue plasminogen activator; 
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 In the EUTOPIA trial, involving the ARB olmesartan me-
doxomil, [207], authors evaluated anti-inflammatory effects of this 
ARB alone and in cotherapy with the HMG-CoA reductase inhibi-
tor pravastatin in patients with essential hypertension and assumed 
vascular microinflammation (ie, hsCRP > 3 mg/L). It was a pro-
spective, double-blind, placebo-controlled, multicenter study, in 
which has been measured a panel of inflammation biomarkers, 
hsCRP, high-sensitivity TNF-, IL-6, ICAM-1, band MCP-1. The 
primary study objective was to evaluate the anti-inflammatory ef-
fect of olmesartan alone and in combination with pravastatin. Blood 
pressure control was achieved with addition of hydrochlorothiazide. 
Olmesartan treatment had already significantly reduced serum lev-
els of hsCRP (-15.1%; P<0.05), hsTNF-alpha (-8.9%; P<0.02), IL-6 
(-14.0%; P<0.05), and MCP-1 (-6.5%; P<0.01) after 6 weeks of 
therapy, whereas placebo treatment (ie, blood pressure reduction) 
had no major effect on inflammation markers. After 12 weeks of 
therapy, hsCRP (-21.1%; P<0.02), hsTNF-alpha (-13.6%; P<0.01), 
and IL-6 (-18.0%; P<0.01) decreased further with olmesartan and 
pravastatin cotherapy, but treatment with pravastatin alone (ie, 
cotherapy with placebo) did not significantly alter inflammation 
markers. In contrast, addition of pravastatin led to a significant 
(P<0.001) reduction in LDL cholesterol serum concentrations in the 
olmesartan and placebo treatment groups (-15.1% and -12.1%, re-
spectively). In this study, treatment with olmesartan significantly 
reduced a panel of inflammation markers currently used to charac-
terize vascular inflammation such as hsCRP, hsTNF-, and IL-6, 
whereas pravastatin monotherapy did not significantly alter levels 
of inflammation markers. After 12 weeks of therapy with olmesar-
tan, the hsCRP level was reduced by > 20%, whereas blood pres-
sure reduction in the placebo treatment group had only minor or no 
effect on inflammation markers. The absence of any effect exerted 
by the HMG-CoA reductase inhibitor pravastatin on inflammatory 
markers found in this study do not reflect other brilliant results 
showed, for example, by rosuvastatin on CRP levels during the 
JUPITER study [255]. Furthermore, in the same trial [207], con-
firming the anti-atherogenetic properties of ARB-blocking drugs, 
olmesartan significantly reduces levels of Osteopontin (p<0.001). 
Osteopontin (OPN; or secreted phosphoprotein 1 [Spp1]), a plei-
otropic cytokine that is broadly expressed and upregulated during 
inflammation, that has been implicated as a key factor in the devel-
opment of atherosclerosis. 
 The comparison of the effects of three different ARBs (losartan, 
irbesartan, and candesartan) on endothelium-dependent vasomotor 
responsiveness, oxidant stress, and on markers of inflammation and 
fibrinolysis in hypertensive patients was investigated in 2004 by 
Koh et al [256]. One hundred twenty-six patients with mild to mod-
erate hypertension participated in this study. Study medications 
were titrated upward from 50 to 100 mg of losartan, from 150 to 
300 mg of irbesartan, and 8 to 16 mg of candesartan over a 2-week 
period if no hypotension (systolic blood pressure < 100 mm Hg) 
was noted. At the end of this time, participants were receiving ei-
ther placebo or 1 of the 3 ARBs per day. The patients were seen at 
>14-day intervals during the study. None was diabetic or a current 
smoker. Compared with placebo, ARB therapies significantly im-
proved the percent flow-mediated dilator response to hyperemia (p 
= 0.019 by ANOVA) with no differences among the groups. Com-
pared with placebo or losartan, irbesartan and candesartan therapies 
significantly lowered plasma levels of plasminogen activator inhibi-
tor type-1 antigen (p = 0.001 by ANOVA) with no differences be-
tween the 2. Only candesartan therapy significantly lowered plasma 
levels of MCP-1 (p = 0.004 by ANOVA) compared with placebo, 
losartan, and irbesartan. However, ARB therapies did not signifi-
cantly lower serum levels of CRP (p = 0.613 by ANOVA). Com-
pared with placebo, therapy with all of the ARBs did not signifi-
cantly lower plasma levels of tissue plasminogen activator antigen 
(p = 0.297 by ANOVA). There were no significant correlations 
between these changes and reduction of systolic blood pressure and 
between these changes and reduction of diastolic blood pressure. 
These data not resolve the controversial data collected in previous 
trials about this topic. 
 ARB valsartan reduced CRP levels in a work by Yasunari et al 
when compared with the CCB amlodipin [257]. In this cross-
sectional and prospective study, participants were randomly as-
signed to either the 80-mg valsartan (n = 52) or 5-mg amlodipine (n 
= 52) group and were treated for eight months. The left ventricular 
mass index (LVMI) was calculated from two-dimensional M-mode 
echocardiography. Formation of ROS by monocytes was measured 
by gated flow cytometry. In addition, CRP, plasma renin activity, 
plasma aldosterone, and traditional risk factors were assessed. Mul-
tiple regression analysis showed a significant correlation between 
LVMI and ROS formation by monocytes and between LVMI and 
CRP. Treatment reduced BP to a similar extent in both groups. 
Valsartan significantly reduced LVMI after eight months, but am-
lodipine had less effect (16% vs. 1.2%, n = 50, p < 0.01). Formation 
of ROS by monocytes was reduced to a greater extent with valsar-
tan than with amlodipine (28% vs. 2%, n = 50, p < 0.01). Valsartan 
but not amlodipine reduced CRP levels. A significant correlation 
between changes in ROS formation by monocytes and LVMI or 
between CRP and LVMI was observed.  
 In 2006 Ridker published data regarding a CRP reduction 
through use of ARB valsartan in association or less to HCTZ, ad-
dressing the issue of whether BP reduction per se lowers CRP lev-
els, or whether selective antagonism of angiotensin type 1 receptors 
may have independent effects to reduce CRP levels. [258]. Authors 
enrolled 1668 stage 2 hypertensives, treated with 160 mg valsartan 
or 160/12.5 mg valsartan/hydrochlorothiazide (HCTZ) once daily 
for 2 weeks with forced titration to 320 mg valsartan or 320/12.5 
mg valsartan/HCTZ for an additional 4 weeks. After 6 weeks, sys-
tolic blood pressure (-25 versus -18 mm Hg; P<0.001) and diastolic 
blood pressure (-14 versus -9 mm Hg; P<0.001) were reduced to a 
greater degree among those allocated to valsartan/HCTZ than to 
valsartan monotherapy. The median change in hsCRP was -0.12 
mg/L among those allocated to valsartan compared with +0.05 
mg/L among those allocated to valsartan/HCTZ, a 13.3% difference 
(P<0.001); this difference between valsartan and valsartan/HCTZ 
was present in all subgroups evaluated despite the fact that blood 
pressure reduction was greater in the combined therapy group. No 
relationship was observed between hsCRP reduction and blood 
pressure. In conclusion, valsartan alone slightly but significantly 
reduced hsCRP levels, in contrast the combination therapy did not 
reduce CRP levels. Thus, these data support the hypothesis that 
ARBs may have anti-inflammatory effects independently of the 
degree of BP reduction. However, the implication of the very small 
change in CRP found with valsartan vs valsartan plus HCTZ re-
mains unclear, as does the therapeutic importance of this difference, 
since in the clinic most patients who receive an ARB also receive a 
thiazide diuretic. 
 In a subsequent post-hoc analysis, Ridker et al [259], evaluated 
stage 2 hypertensives in order to assess effectiveness of the ARB 
valsartan 320 mg (n = 607) or the combination therapy with valsar-
tan/hydrochlorothiazide 320 mg/12.5 mg (n = 581) for 6 weeks to 
evaluate whether valsartan soluble ICAM-1 or soluble VCAM-1. 
After treatment, median (interquartile range) sICAM-1 levels were 
reduced by both valsartan alone (-4 (-25 to 16) ng/ml, p = 0.005) 
and valsartan/hydrochlorothiazide (-4 (-22 to 17) ng/ml, p = 0.028), 
such that the between-group difference was not significant (p = 
0.7). The median percentage change from baseline was small in 
both groups (-1.6% and -1.3%). Median (interquartile range) 
sVCAM-1 levels were reduced by both valsartan alone (-13 (-70 to 
42) ng/ml, p = 0.001) and valsartan/hydrochlorothiazide (-26 (-88 
to 38), p<0.001); the between-group difference was of borderline 
significance (p = 0.051). The median percentage change from base-
line was small (-2.1% and -4.4%). The reduction of sICAM-1 and 
sVCAM-1 was independent of blood pressure reduction (rs = 0.03 
and rs = 0.06 for the relationship of change in systolic blood pres-
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sure with change in sICAM-1 and sVCAM-1, respectively). In con-
trast to hsCRP, both valsartan and valsartan/hydrochlorothiazide 
induced reductions of sICAM-1 and sVCAM-1 in the Val-MARC 
trial. These effects, although statistically significant, were rather 
small and independent of changes in blood pressure. 
 Touyz et al, tested the hypothesis that in patients with hyperten-
sion and type 2 diabetes, hence with a condition of low-grade sys-
temic inflammation, blood pressure (BP) reduction with the ARB 
valsartan, or with a beta blocker, atenolol, is associated with a de-
creased inflammatory response [260]. Normotensive subjects and 
hypertensive patients with type 2 diabetes (40 to 70 years of age) 
participated in the study. Patients (n = 28) were randomized to dou-
ble-blind treatment for 1 year with valsartan (80-160 mg) or at-
enolol (50-100 mg) daily, added to previous therapy. Age-matched 
controls (n = 12) were also studied. Serum levels of cytokines (IL-
6, IL-18), chemokines (MCP-1), and adhesion molecules (sICAM, 
sE-selectin) were measured by enzyme-linked immunosorbent as-
say (ELISA) as indices of systemic and vascular inflammation, 
before and 1 year after treatment. BP was similarly reduced by 
valsartan and atenolol. Glycemic control and lipid profiles were 
comparable in the two groups and did not change significantly with 
antihypertensive therapy. Serum levels of all inflammatory markers 
were increased in patients before treatment (by two- to four-fold vs. 
controls, P < .05). IL-6, IL-18, sICAM, and MCP-1 levels were 
reduced by valsartan (three-fold, P < .05). Only IL-18 was reduced 
by atenolol compared with pretreatment levels (P < .05). These data 
indicate that proinflammatory mediators are significantly increased 
in hypertensive type 2 diabetic patients and that despite similar BP 
lowering by valsartan and atenolol and similar glucose levels in 
both treated groups, global inflammatory status was improved only 
in the valsartan group. These findings suggest convincingly that 
antihypertensive treatment, particularly with an ARB, ameliorates 
inflammatory processes in diabetic hypertensive patients, through 
effects which are independent of BP and glycemic control. Interest-
ingly these effects appeared to be independent of actions of statin 
and aspirin, which in their own right have been implicated to have 
anti-inflammatory properties. This is suggested by the facts that an 
equal number of patients were taking aspirin in the valsartan and 
atenolol groups and that more patients in the atenolol group were 
taking statins than in the valsartan group. 
 In conclusion, results obtained by trials accomplished using 
ARBs seem to be more univocal to confirm, although in various 
extent, an anti-inflammatory effect of drugs blocking AT1 receptor. 
In order to explore more deeply the modulatory effects on inflam-
mation of a more complete blockage of RAAS, future studies may 
explore different strategies with a more efficient blockage of the 
renin-angiotensin-aldosterone system by, for example, simultane-
ously acting on the ACE and the AT1 angiotensin receptors. 
CONCLUSIONS 
 Vascular inflammation is widely recognized as a main element 
of pathophysiology of cardiovascular disease. The hypertensive 
vascular damage model as well as the atherosclerotic damage, at-
tributes a pathogenetic role to reclutation and activation of inflam-
mation-related cells and to various inflammatory mediators. Thus, 
although the reduction of BP values is the primary goal necessary 
for obtain the decrease of cardiovascular events in hypertensive 
patients, the reduction of low-grade inflammation in hypertension 
may be an interesting and important target in order to reduce the 
cardiovascular morbidity and mortality. 
 Behavioural and pharmacological approaches to control high 
BP may decrease vascular inflammation independently of BP re-
duction in patients with hypertension, resulting in reduced cardio-
vascular events in randomized clinical trials. Many studies have 
demonstrated that Ang II and other components of the RAA system, 
such as aldosterone and MR, contribute to the inflammatory re-
sponse.  
 Among other antihypertensive agents, RAAS-suppressing drugs 
have shown more potent anti-inflammatory properties unrelated to 
BP-lowering effect of this class of drugs, but more probably the 
result of a direct antagonism of the pro-inflammatory effects in-
duced by angiotensin II. 
 The different classes of RAAS suppressing agents have differ-
ent mechanisms of action and different ancillary effects beyond BP 
reduction. How more we examine the RAA system, so more new 
questions emerge about its function. ACEis are able to reduce the 
breakdown of bradykinin, and this molecule can cause the most 
frequent untoward effects of these drugs (cough, angioedema) but it 
is believed also as an important contributor to the protective cardio-
vascular effects exerted by them [261]. How relevant is its contribu-
tion to the pleiotropic effects provided by them? Different ACEis 
exerts different degree of block of the tissue ACE system. How 
important is this different degree of this difference for the plei-
otropic effects? And also: How significant is the role of the AT2 
receptor stimulation, as a consequence of the antagonism at the 
AT1 receptor site [262], in the beneficial therapeutic effects of 
ARBs? 
 Nevertheless of these unresolved issues, RCT data clearly dem-
onstrate that the inhibition of the renin-angiotensin system repre-
sents a pivotal approach for reducing atherosclerosis and its dra-
matic complications, such as stroke and myocardial infarction (MI). 
ACE inhibitors and ARBs are well-established pharmacological 
tools in both primary and secondary prevention of atherosclerotic 
cardiovascular disease and part of these results are certainly due to 
a direct anti-inflammatory activity. The real extent of these effects 
and the real differences among the different drugs in different 
pathologic contexts and in various populations need further studies. 
 Taking into account all the new informations about the drugs 
controlling the RAAS, although many point may be even clarified, 
probably the question arose by Chobanian in New England Journal 
of Medicine not so long ago [263]: “Does it matter how hyperten-
sion is controlled?” could now have a more clear answer. 
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